MULTIFACTORIAL MODULATION OF THE BLOOD-BRAIN BARRIER: RELATIONSHIP TO STROKE by Zhang, Bei
University of Kentucky 
UKnowledge 
Theses and Dissertations--Nutritional Sciences Nutritional Sciences 
2013 
MULTIFACTORIAL MODULATION OF THE BLOOD-BRAIN BARRIER: 
RELATIONSHIP TO STROKE 
Bei Zhang 
University of Kentucky, bei.zhang@uky.edu 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Zhang, Bei, "MULTIFACTORIAL MODULATION OF THE BLOOD-BRAIN BARRIER: RELATIONSHIP TO 
STROKE" (2013). Theses and Dissertations--Nutritional Sciences. 5. 
https://uknowledge.uky.edu/nutrisci_etds/5 
This Doctoral Dissertation is brought to you for free and open access by the Nutritional Sciences at UKnowledge. It 
has been accepted for inclusion in Theses and Dissertations--Nutritional Sciences by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained and attached hereto needed written 
permission statements(s) from the owner(s) of each third-party copyrighted matter to be 
included in my work, allowing electronic distribution (if such use is not permitted by the fair use 
doctrine). 
I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive 
and make accessible my work in whole or in part in all forms of media, now or hereafter known. 
I agree that the document mentioned above may be made available immediately for worldwide 
access unless a preapproved embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s dissertation 
including all changes required by the advisory committee. The undersigned agree to abide by 
the statements above. 
Bei Zhang, Student 
Dr. Michal Toborek, Major Professor 
Dr. Howard Glauert, Director of Graduate Studies 
 
 
 
  
 
MULTIFACTORIAL MODULATION OF THE BLOOD-BRAIN BARRIER: 
RELATIONSHIP TO STROKE 
 
DISSERTATION 
 
 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the 
College of Medicine, Graduate Center for Nutritional Sciences 
at the University of Kentucky 
 
 
By 
Bei Zhang 
Lexington, Kentucky 
 
 Director: Dr. Michal Toborek, Professor of Nutritional Sciences 
Lexington, Kentucky 
 
2013 
 
Copyright © Bei Zhang 2013 
 
 
 
 
The blood-brain barrier (BBB) is a dynamic interface, mainly consisting of highly 
specialized brain microvascular endothelial cells (BMECs) that segregate the central 
nervous system (CNS) from the peripheral circulation. Impairment of the BBB, due to 
disruption of tight junction (TJ) proteins and inflammatory responses, may initiate and/or 
contribute to the progress of CNS disorders, including stroke. Stroke is the second 
leading cause of death worldwide. It has been shown that aging and environmental 
pollutants can induce brain endothelium dysfunction, and are considered as risk factors 
for stroke.  
 
Deficiency of telomerase is highly linked with aging-associated vascular diseases. 
Evidence indicates that patients with shorter telomere length are at higher risk of heart 
disease or stroke. Results in this dissertation address the influence of telomerase reverse 
transcriptase (TERT), a key component of telomerase, on the BBB integrity in the 
context of ischemic stroke induced brain injury. Our results indicate that aging-related 
BBB alterations aggregate the stroke outcomes by inducing oxidative stress and 
stimulating proinflammatory responses on the brain microvessels.  
 
The ability of the BBB to protect the brain from harmful compounds indicates 
that the BBB may be targeted by chemical toxicants in the peripheral circulation. 
Polychlorinated biphenyls (PCBs) are persistent organic pollutants that frequently bind to 
nanoparticles (NPs) in the environment. Our results demonstrate that binding PCB153, 
one of the most abundant PCB congeners in the environment, to silica nanoparticles 
(PCB153-NPs) potentiates cerebrovascular toxicity and stroke outcomes via stimulation 
of inflammatory responses and disruption of BBB integrity. These events are mediated by 
activation of toll-like receptor 4 (TLR4), which subsequently recruits tumor necrosis 
factor-associated factor 6 (TRAF6) and initiates the production of multiple inflammatory 
mediators. 
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MULTIFACTORIAL MODULATION OF THE BLOOD-BRAIN BARRIER: 
RELATIONSHIP TO STROKE 
 
 
Research presented in this dissertation demonstrates that aging and environmental 
pollutants play crucial roles in modifying the function of the BBB through alterations of 
inflammatory responses and TJ protein expression, which further contribute to the 
progression of stroke-induced cerebral ischemic injury. 
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Chapter one: Introduction 
1. Background  
1.1. Pathology of Stroke 
1.1.1. Overview 
Stroke, which refers to a diseased condition caused by the occlusion or 
hemorrhage of blood cerebral vessels, is the second leading cause of death worldwide [1]. 
Over 5.7 million people die from stroke in every year, and more than 85% of these deaths 
are in developing countries [1]. According to data from 2006, stroke accounted for 
roughly 1 of each 18 deaths in the United States. About every 40 seconds, someone in the 
United States has a stroke [2]. The report of the National Institute of Neurological and 
Communicative Disorders and Stroke (NINCDS) data bank showed that 70% of strokes 
are caused by cerebral ischemia, 27% are due to cerebral hemorrhage, and 3% are caused 
by some unknown reasons [3]. Stroke can be classified into four major types: primary 
intracerebral hemorrhage, subarachnoid hemorrhage, ischemic stroke and undetermined 
stroke. The etiologies of stroke include atherothrombosis of large arteries, embolism from 
the heart or cerebropetale arteries, sudden occlusion of small penetrating arteries (lacunar 
stroke), arteritis, arterial dissection, and various genetic and hematological disorders [4]. 
Ischemic stroke can be triggered by in situ thrombosis, embolism, or relative 
hypoperfusion. In all cases, stroke induces brain cell dysfunction, neurological deficits, 
and ultimately leading to death. 
 
1.1.2. Risk factors 
Hypertension, hyperlipidemia, atrial fibrillation, and myocardial infarction are the 
primary risk factors for the atherothrombotic stroke, cardioembolic stroke and primary 
intracerebral hemorrhage. Several others, classified as modifiable and non-modifiable 
factors, also tend to increase the incidence of stroke. For example, risk factors like age, 
gender, ethnicity, and heredity have been identified as non-modifiable, whereas 
numerous modifiable factors, such as smoking, alcohol intake, daily diet and physical 
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activity, are considered as targets to address the prevention of stroke in the appropriate 
perspectives. Additionally, environmental pollution is also recognized as a risk factor for 
vascular disease and stroke [5].  
Age is recognized as the most significant risk factor for stroke. After the age of 55, 
the rate of stroke rises by a factor larger than two for each consecutive 10 years in both 
sexes [6]. Age-related brain changes are associated with increased blood-brain barrier 
(BBB) permeability, which is proposed as an important mechanism in the initiation or 
aggravation of cerebral microvascular disease. Animal studies have shown that the initial 
step in the lacunar stroke is plasma leakage into the vessel wall and surrounding brain 
parenchyma [7]. With normal aging, the brain capillary surface area reduces while the 
capillary diameter, length, and volume increase. This degeneration of the brain vascular 
structure and function may lead to lipohyalinosis, lumen narrowing, and blood flow 
reduction. Cerebral hypoperfusion leads to oligemia and subsequent disruption of the 
microcirculation, which further induce the BBB damage and enhance the intrinsic 
susceptibility of brain cells to ischemic injury [8, 9].  
Recent evidence indicates that environmental pollution is a risk factor for vascular 
disease and stroke. The most important environmental pollutants include ambient 
particulate matter [10] and persistent organic pollutants (POPs), such as chlorinated 
pesticides, dioxin and polychlorinated biphenyls (PCBs) [11, 12]. Because of their 
lipophilicity and resistance to degradation, chlorinated organic compounds have high 
tendency to accumulate in the human body, and thus increase the vascular risks of 
hypertension, diabetes mellitus, ischemic heart disease, and atherosclerosis. Laboratory 
evidence demonstrated that animals exposed to PCBs show elevation of triglycerides and 
serum lipids. Exposure to dioxin induces endothelium release of reactive species, which 
promote adhesion of foam cells and formation of atherosclerosis with the vascular wall 
lesions in brain, heart, and renal arteries [13]. Additionally, an epidemiological study 
indicated that living close to POP contaminated waste sites is significantly associated 
with increased risk of ischemic stroke [14]. 
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1.1.3. Risk factor-induced alteration of cerebral blood vessels 
Stroke risk factors alter the structure and function of blood vessels by promoting 
atherosclerosis and stiffening of arteries, as well as by inducing narrowing, thickening, 
and tortuosity of arterioles and capillaries. These morphological changes in cerebral 
vasculature are often associated with regulation and/or reduction in cerebral blood flow 
(CBF). Endothelial dysfunction (ED) is associated with aging and other risk factors and is 
associated with vascular-related diseases, such as stroke[15]. ED is characterized by 
increased permeability, altered vasodilatation, increased vascular reactivity, platelet 
activation, and enhanced thrombogenicity, as well as leukocyte adhesion and monocyte 
migration. Increased oxidative stress and inflammation in the vascular wall are the main 
causes for ED. Under oxidative stress, biological inactivation of nitric oxide (NO) by the 
superoxide weakens the beneficial effect of NO-mediated regulation of vascular tone, 
which subsequently leads to the production of the deleterious peroxynitrite and 
vasoconstriction [16, 17]. Loss of the protective effects of NO also promotes platelet 
aggregation, leukocyte adhesion, and smooth muscle proliferation, which are key steps in 
the formation of vascular inflammation [18]. Additionally, reactive oxygen species (ROS) 
can induce inflammation by increasing BBB permeability through upregulation of 
vascular endothelial growth factor (VEGF) and triggering activation of NF-κB, which 
promotes the expression of cytokines, matrix remodeling enzymes, and proinflammatory 
genes. Matrix remodeling, together with smooth muscle cell migration and intimal 
hyperplasia which are also provoked by oxidative stress and inflammation, are critical 
factors for atherosclerosis and vascular structure alterations [19]. Thus, risk factors like 
aging and POPs may exert deleterious effects on cerebral blood vessels through oxidative 
stress and vascular inflammation; however, it remains to be determined how individual 
risk factor triggers the activation of one or both of these mechanisms.  
 
1.1.4. Mechanisms of ischemic brain injury  
Ischemic stroke begins with severe focal hypoperfusion. The ischemic core is the 
rapidly and irreversibly injured territory with severely impaired blood flow. The primary 
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mechanism of cell death in the ischemic core is energy failure. At the periphery region of 
ischemic core, where the blood flow arises from adjacent vascular territories, the so-
called ischemic penumbra, cell death develops more slowly because of partially 
preserved energy metabolism. In the ischemic penumbra, several deleterious mechanisms 
contribute to the ongoing cellular injury and infarct progression, which ultimately result 
in the demise of the ischemic penumbra within hours after stroke onset [20].  
 
1.1.4.1. Energy failure, excitotoxicity and ionic imbalance 
Brains consume relatively high content of oxygen and glucose as compared to 
other organs. The energy supply for a functional brain is almost exclusively from 
oxidative phosphorylation to generate adenosine triphosphate (ATP) [21]. The first 
consequence of focal hypoperfusion is the depletion of essential substrates, especially 
oxygen and glucose, which subsequently causes the failure of ATP production for energy. 
In addition, depletion of oxygen supply to the brain leads to anaerobic glycolysis and 
lactate accumulation [22, 23]. Elevation of lactate level is considered as a possible cause 
of secondary damage which leads to increased infarct volume of the brain and 
neurological deficits [24, 25]. The failure of cellular bioenergetics quickly results in 
depolarization of energy-dependent ion channels on the neurons and glia [26, 27], 
followed by the activation of somatodendric and presynaptic voltage-dependent Ca2+ 
channels and the release of excitatory amino acids into the extracellular space. The 
increase of extracellular excitatory neurotransmitters, especially glutamate, 
overstimulates the glutamate receptors, such as amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA), kainate and N-methyl-d-aspartic acid (NMDA), which 
consequently leads to influx and build-up of intracellular Na+, Cl− and Ca2+ levels [28, 
29]. Furthermore, water passively passes the cell membrane following the influx of ions, 
resulting in brain edema [30].  
 
1.1.4.2. Oxidative stress  
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Oxidative stress occurs when the generation of free radicals overwhelms the 
endogenous cellular antioxidant defenses. Because of the low capacity of endogenous 
antioxidants in neurons [31], the brain is highly vulnerable to reactive oxygen species 
(ROS). Following brain ischemia, increased levels of intracellular Ca2+, Na+ and ADP 
stimulate mitochondria to generate deleterious amount of ROS. Additionally, ischemia 
also triggers nitric oxide synthase (NOS) activation, which consequently increases the 
NO production. Interaction of NO and superoxide can yield highly toxic peroxynitrite, a 
compound that decomposes spontaneously to produce the hydroxyl radical, which is the 
most reactive oxygen radical and probably causes the most tissue injury [32]. The 
increase of free radical can induce numerous toxic cellular effects, such as impairing 
enzyme activity, releasing Ca2+ from intracellular stores, damaging cytoskeleton and 
DNA, protein denaturation, lipid peroxidation and mitochondrial dysfunction [33]. 
Besides cellular damage, oxidative stress also contributes to the elevation of BBB 
permeability following brain ischemia through activation of matrix metalloproteinases 
(e.g. MMPs) [34, 35], as well as direct damage on endothelial cells [36]. Furthermore, the 
interaction between NO and superoxide induces vasoconstriction hereby reducing the 
cerebral blood flow. 
 
1.1.4.3. Post-ischemic inflammation 
Inflammation associated with cerebral ischemia involves the induction of 
cytokines, chemokines, and adhesion molecules at the level of brain endothelial cells, in 
coordination with the trafficking and transmigration of circulating inflammatory cells, as 
well as the activation of resident brain cells. Continuing amplification of inflammatory 
responses contributes to severe cellular damage, disruption of microvascular stasis, and 
impairment of BBB function.  
In response to cerebral ischemia, cytokines are upregulated in the brain and 
expressed not only in cells of the immune system, but also in resident brain cells, 
including glia, neurons and endothelial cells[37-39]. The widely investigated cytokines 
related to inflammation in cerebral ischemia are interleukin-1 (IL-1), TNF-α, interleukin-
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6 (IL-6), interleukin-10 (IL-10) and transforming growth factor-β (TGF-β). IL-1 and 
TNF-α are associated with induction of adhesion molecules on endothelial cells during 
ischemia/reperfusion (I/R) [40]. IL-6 is largely considered to be a proinflammatory 
cytokine, but whether it plays a significant role in ischemic stroke is far from clear. IL-10 
is recognized as an anti-inflammatory cytokine, acting by inhibiting IL-1 and TNF-α and 
also by suppressing cytokine receptor expression as well as receptor activation. Elevation 
of proinflammatory cytokines and reduction of the anti-inflammatory IL-10 are related to 
larger infarctions and poor clinical outcomes [41].  
Cytokines also stimulate the production and release of chemokines, which play an 
important role in cellular communication and inflammatory cell recruitment in the host 
defense. Expression of chemokines after the onset of cerebral ischemia is thought to be 
deleterious because of their critical role in leukocyte infiltration[42]. It also suggested 
that, in addition to chemotactic properties, chemokines can directly affect BBB 
permeability. For example, exogenous monocyte chemotactic protein-1 (MCP-1) 
increased BBB permeability 17-fold in vitro and caused alterations in tight junction (TJ) 
proteins, which indicate that MCP-1 may participate in opening the BBB [43]. 
Subsequent to the activation of cytokines and chemokines, the induction of 
adhesion molecules starts. Adhesion molecules are important mediators for leukocytes 
infiltration into the brain parenchyma. During the early stages of ischemia, E-selectins 
and P-selectins which mediate the interaction between leukocytes and the vascular 
endothelium, are upregulated. Once slowed by binding to selectins, contact between 
leukocyte integrins and endothelial intercellular adhesion molecule-1 (ICAM-1) mediates 
leukocyte adhesion to and migration through the layer of endothelium, whereas 
monocytes undergo a similar process by binding to vascular cell adhesion molecule 
(VCAM) [44]. Inflammatory cells adherence to the cerebral vessel wall or transmigration 
into the CNS, which are promoted by adhesion molecules, may contribute to the BBB 
disruption and worsen the stroke outcomes. 
Activation of enzyme activity is also involved in the inflammatory cascade. Upon 
brain ischemia, accumulation of intracellular calcium activates the phospholipase A2, 
which subsequently triggers the hydrolysis of glycerophospholipids, resulting in releasing 
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of arachidonic acid (AA). AA metabolites are potent mediators that contribute to post-
ischemic inflammation in the brain [45]. AA can be metabolized by two different 
enzymes, which are cyclooxygenase (COX) or lipoxygenase (LOX). COX-1 is 
constitutively expressed in microglia, leukocytes and many other cell types during brain 
injury [46], while upregulation of COX-2 is observed not only in ischemic core, but also 
penumbra [47]. In addition, COX-2 exerts toxic effects through prostaglandins rather 
than reactive oxygen radicals [48]. However, the role of the LOX pathway is less clear 
than the COX pathway in brain ischemia. Leukotrienes (e.g. LTC4) are metabolites that 
are generated via LOX pathway. They are chemoattractants and may play role in BBB 
dysfunction, edema and neuronal death after ischemia/reperfusion [49, 50]. During brain 
ischemia/reperfusion, biphasic elevation of AA and LTC4 has been reported and appears 
to relate to biphasic patterns of BBB disruption[49]. 
 
1.2. Blood-brain barrier (BBB) 
1.2.1. Overview 
The BBB is a highly specialized brain endothelial structure that is localized at the 
interface between the peripheral circulation and the CNS. The primary responsibilities of 
the BBB are to ensure constant nutrients supply for the brain and, at the same time, limit 
paracellular movement of the hydrophilic solutes and trans-endothelial migration of 
circulating blood cells and pathogens.  
 
1.2.2. BBB in homeostasis 
Brain endothelial cells are different from non-brain endothelial cells because of 
the presence of intercellular tight junctions (TJs). The tightly sealed monolayer of brain 
endothelium by the TJs primarily confers the low paracellular permeability and high 
transendothelial electrical resistance (TEER) of the BBB [51]. The maintenance of the 
TJs is managed by transmembrane proteins, occludin, claudins and junction associated 
molecules (JAMs), as well as several cytoplasmic proteins, such as zonula occludens 
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(ZOs) (Fig. 1.1). Occludin is highly expressed in brain endothelial cells and can be 
consistently detected along the cell borders [52]. Multiple phosphorylation sites, which 
present on occludin serine and threonine residues, are critical elements for the association 
of occludin with the cell membrane and the regulation of the BBB permeability [53]. The 
cytoplasmic C-terminal domain of occludin is associated with accessory proteins, ZO-1 
and ZO-2, enabling the connection of occludin with the cytoskeleton [54]. ZO-1 (220 
kDa) and ZO-2 (160 kDa) are phosphoproteins, which can form heterodimers with each 
other. ZOs serve as recognition proteins for TJ placement, and also anchor the 
transmembrane proteins to the actin cytoskeleton through their proline-rich carboxy-
terminus [54]. ZO proteins have also been indicated in recruitment of the transmemrane 
TJ components to the apical part of the cellular membrane [55]. Claudins, which locate 
proximately to occludin at the cellular membrane, are a family of more than 24 proteins 
[56]. The homophilic and/or heterophilic interactions of the claudins formed by the 
extracellular loops secure the tight connections of the cell monolayers [57]. The 
contiguous staining of claudins can be detected along endothelial cell borders, which 
suggests that claudins primarily constitute the TJs, while occludin enhances the tightness 
further [55]. Junctional adhesion molecules (JAMs) are members of the immunoglobulin 
super family. JAMs mediate the attachment of adjacent cell membranes via a homophilic 
or heterophilic interaction [58]. Several JAM proteins have been identified, with JAM-A 
shown to be significantly expressed on the brain ECs. Studies indicate that homophilic 
JAM-A interactions are critical in the stabilization of cellular junctions and the reduction 
of paracellular permeability [59, 60].  
  
9 
 
 
 
 
 
 
 
 
Figure 1.1. The molecular composition of tight junctions (TJs) between two adjacent 
brain endothelial cells. The TJs consist of transmembrane proteins, including occludin, 
claudins, and junctional adhesion molecules (JAMs), which are linked to actin 
cytoskeleton by accessory proteins such as zonula occluden-1 (ZO-1).   
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Another distinctive character of brain endothelial cells is the polarized expression 
of membrane receptors and transporters, which can be generally classified into five main 
categories: carrier-mediated transport, ion transport, active efflux transport, receptor-
mediated transport, and caveolae-mediated transport [51]. They control the active 
transport of nutrients to the brain and the efflux of potentially toxic compounds from the 
cerebral to the vascular compartment. For example, nutrients such as glucose, nucleosides, 
purines, amines and vitamins are transported by carrier-mediated transport systems from 
the blood to the brain [61, 62], while efflux of molecules from the brain endothelium is 
facilitated by ATP-binding cassette (ABC) transporters [63]. The high density of 
mitochondria in the brain endothelial cells reflects high energy demands for active ATP-
dependent transporters, such as sodium pumps, which regulate the exchange of ions [64]. 
In addition, receptors for large proteins, such as insulin and transferrin receptors, are 
found in the caveolar membranes, which are responsible for the transcellular permeability 
by regulating endocytosis, transcytosis, and signaling in lipid-based microdomains of the 
BBB [65].  
In close proximity to brain endothelial cells, pericytes, glial cells (e.g., astrocytes, 
and microglia), and neurons, together with the basal lamina form a functional unit, 
referred to as a neurovascular unit (NVU) (Fig. 1.2). The close interaction of different 
cell types with each other allows for effective paracrine regulations that are important for 
maintaining the brain homeostasis as well as modulating the disease processes. Under 
cerebrovascular disorders, such as stroke, vascular dementia, or hypertension, changes in 
endothelium and pericytes can directly disturb neuronal and synaptic functions via 
alteration of the blood flow, BBB permeability, enzymatic functions, secretion of trophic 
factors and matrix molecules, expression of vascular receptors, or induction of 
ectoenzymes. In response to a vascular insult, signals from neurons, astrocytes and 
activated microglia can further amplify the neuronal injury and synaptic dysfunction.  
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Figure 1.2. Schematic of the neurovascular unit (NVU) of the blood-brain barrier (BBB). 
The capillary endothelial cells, together with the pericytes, are surrounded by basal 
lamina and astrocytic perivascular endfeet. Astrocytes also provide the cellular 
interaction with neurons. 
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1.2.3. BBB dysfunction in stroke 
Under ischemic stroke conditions, BBB dysfunction results in increased 
paracellular permeability, which directly contributes to cerebral edema, hemorrhagic 
transformation, and increased mortality. Several mechanisms, occurring in a phasic 
manner, contribute to the ischemic damage of the BBB. As soon as 2 hours after the onset 
of ischemia, dissolution of the endothelial basal lamina starts. This is rapidly followed by 
an increase in BBB permeability. Upon reperfusion, a biphasic increase of BBB 
permeability may occur. The multi-phasic phenomenon of this permeability change is 
determined by various factors, including the duration of ischemia, degree of reperfusion, 
and the experimental models of stroke that are used for assessment. The increase of 
paracellular permeability is generally associated with the alteration of TJ protein 
expression and/or the redistribution of TJ protein along the cellular membrane. It has 
been shown that a reduction in TEER is accompanied by a decreased claudin-5 
expression under the hypoxic conditions [66], whereas hypoxia induced increase of 
paracellular permeability has been observed along with the disruption of occludin, ZO-1, 
and ZO-2 membrane localization [67]. In response to brain ischemia, accumulated 
bradykinin, vascular endothelial growth factors, and thrombin initiate the increase of 
intracellular calcium concentration, whose principle effect in the endothelial cells is the 
activation of calcium/calmodulin-dependent myosin light chain kinase (MLCK) [68], 
inducing actin reorganization, changes of cell shape, and thus increased BBB paracellular 
permeability [69]. Oxidative stress is also an early stimulus for BBB disruption and 
triggers the cellular release of MMP-9 from neurons, astrocytes, pericytes, and 
endothelial cells, which results in digestion of the endothelial basal lamina. In the later 
phase, severe BBB damage resulting from more complicated mechanisms appears, such 
as induction of proinflammatory cytokines, followed by chemokines and adhesion 
molecules expression on the activated endothelium [70]. The expression of cytokines and 
adhesion molecules precedes the infiltration of leukocytes, which, together with activated 
microglia, further enhances the inflammatory responses and the production of toxic free 
radicals [70, 71]. The damaged BBB allows leakage of blood constituents into the brain 
parenchyma. Extravasation of high molecular weight components, which is followed by 
water due to osmosis, concomitantly leads to vasogenic edema and intracranial 
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hypertension. Particularly, extravasation of red blood cells may lead to hemorrhagic 
transformation in the injured brain.  
 
1.3. Telomere and telomerase 
1.3.1. Overview 
Telomeres are specialized DNA structures localized at the ends of chromosomes 
and primarily function to maintain the genome stability. Telomeres consist of non-coding 
tandem repeats of the TTAGGG sequences and telomere-specific proteins [72]. Because 
of the complications exhibited during DNA replication called-- the end replication 
problem, telomeres continuously lose the guanine-rich repeats in a manner that is coupled 
with cell division [73]. The shortening of telomere is prevented by telomerase, an enzyme 
which can synthesize telomeric DNA and maintain the function of telomere [74]. Human 
telomerase is composed of two core components: telomerase RNA component (TERC) 
that serves as a template, and telomerase reverse transcriptase (TERT), which is a 
catalytic subunit of telomerase [75]. The enzyme activity of telomerase is detectable in 
early fetal development, but is repressed in most of the postnatal somatic tissues [72, 76]. 
In proliferating cells without functional telomerase, telomeres gradually erode with time 
and mitotic division, and the cells eventually undergo senescence. Although telomerase 
repression has been extensively studied as a mechanism for tumor suppressor in cancer 
research, increasing evidence from epidemiology and laboratory data indicates that 
shortening of telomere and repression of telomerase are involved in a broad spectrum of 
human diseases. For example, patients with Dyskeratosis congenita, a congenital disorder, 
are diagnosed with shortened telomeres because of the telomerase mutation. In addition, 
telomere length shortening has been recognized as a marker of biological aging and may 
also play an important role in age-related diseases, such as cardiovascular diseases and 
stroke [77]. Individuals with a telomere length shorter than the average are at higher risk 
of heart disease or stroke; on the other hand, it has also been revealed that telomere 
shortening in humans suffering from long-term chronic stress is more accelerated as 
compared to the people of a similar age [78-81]. The laboratory evidence suggested that 
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telomerase transduction in the cells can extend the replication capacities, protect cells 
from stress, and improve functional activities while the differentiation and growth of the 
cells are still under control [77]. Thus, telomerase may be a novel target for the treatment 
of diseases associated with telomere loss and aging.  
 
1.3.2. The roles of telomerase reverse transcriptase (TERT) in stroke 
In the developing brain, TERT expression can be detected in neuronal progenitor 
cells, embryonic neurons and early postnatal neurons; however, TERT level declines 
progressively after birth [82-84]. Recently, studies revealed that TERT expression is 
inducible in the damaged brain cells of adult animals subjected to the occlusion of middle 
cerebral artery, indicating an important role of TERT in ischemic brain injury. 
Additionally, under pathophysiological conditions, such as ischemic stroke, TERT has 
been reported to reduce the excitotoxity, promote neuronal survival and differentiation, 
and increase angiogenesis in the CNS [85, 86].  
As mentioned before, excitotoxicity, which is mediated by over-stimulation of 
NMDA receptors, is one of the main mechanisms to induce neuronal death following 
brain ischemic injury. A recent study reported that injection of a lethal dosage of NMDA 
accelerated the death of TERT-deficient mice, while transgenic mice with overexpression 
of TERT showed an improved survival rate as compared to wild-type littermates [87]. In 
addition, it was demonstrated that transgenic mice overexpressing TERT showed 
significantly decreased infarct volume after permanent occlusion of the middle cerebral 
artery. The reduced brain injury is associated with the defensive role of TERT, whose 
overexpression protects against NMDA receptor-induced excitotoxicity through 
decreasing cytosolic accumulation of Ca2+ while enhancing Ca2+ uptake by mitochondria 
[86]. These results suggest that TERT may protect NMDA-mediated excitotoxicity 
through a mitochondrial related signaling pathway.  
The anti-apoptotic effect of TERT has been observed in various cell types 
including neuronal cells [88-90]. Subsequently, it has been suggested that TERT can 
protect neurons against apoptosis induced by DNA damage [84], oxidative stress and 
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ischemia [86]. Because of the reverse transcriptase activity of TERT, the anti-apoptosis 
effect of TERT may work through the maintaining of the chromosome integrity and 
preventing DNA damage, an event which is also involved in the apoptosis induced by 
ischemic injury [91]. Additionally, studies also reported that TERT can suppress 
apoptosis induced by dysfunction of mitochondria following cerebral ischemia [86, 87]. 
TERT is normally localized in the nucleus; however, the export of TERT from the 
nucleus to the mitochondrial matrix has been detected under stressed conditions, 
indicating an important role of TERT on mitochondria [92, 93]. It has been shown that 
TERT can suppress apoptosis before the release of cytochrome c and apoptosis-inducing 
factors from mitochondria. Further studies suggested that TERT regulates apoptosis by 
interacting with the Bcl-2 family [94, 95]. In addition, accumulating research reported 
that TERT can maintain the function of mitochondria and thus suppress apoptosis by 
protecting mitochondrial DNA (mtDNA), reducing the production of ROS, increasing the 
mitochondrial membrane potential, and facilitating mitochondrial coupling [92, 93, 96]. 
Thus, the role of TERT in mitochondria-mediated apoptosis may also account for its 
protective effect in cerebral ischemic injury.  
Angiogenesis plays a vital role in the repair mechanisms following a brain 
ischemic injury. It has been shown that sustained TERT activity contributes to the 
angiogenic properties of cultured endothelial progenitor cells [97]. Additionally, in vivo 
studies reported that TERT significantly induced new capillary formation in ischemic 
tissue. The underlying neo-angiogenic mechanisms of this study include VEGF-mediated 
induction of telomerase enzyme activity and expression of TERT through the nitric oxide 
signaling pathway, and telomerase-dependent endothelial cell differentiation and anti-
apoptosis [98]. On the other hand, down-regulation of TERT results in decreased 
neovascularization, which is associated with reduced cell proliferation and expression of 
key molecules involved in angiogenesis, such as VEGF [99]. Furthermore, it has been 
reported that TERT knockdown in vivo leads to suppression of genes related to anti-
apoptosis and angiogenesis.  
 
1.4. Polychlorinated biphenyls (PCBs) 
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1.4.1. Overview  
PCBs are known as chlorinated hydrocarbons and were first synthesized in 1881. 
They are oily, light colored liquids with special physical properties including high flash 
points, chemical stability, and low electrical conductivity. Due to these characteristics, 
PCBs were widely applied to lots of industrial and commercial purposes, such as 
pigments, transformers, and rubber products. Industrial or commercial PCBs used in 
those products were chemical mixtures which consisted of different chlorinated biphenyls 
components. In the United States, most of the commercial PCB mixtures are recognized 
by their trade name—Aroclor, the most commonly known PCB mixture. Because of a 
wide range of toxic effects of PCBs, they were banned by the EPA in 1979, and 
ultimately out of use in 1983. However, PCBs can still be identified in approximately 
one-third of the sites listed on the National Priorities List (NPL), a list associated with the 
Superfund Program [100]. PCBs are resistant to natural chemical and biological 
processes, thus, banned PCB production does not imply reduced toxicity. In many parts 
of the world, wide distribution of PCBs in the environment and their adverse health 
effects on humans and animals have already raised the concern of investigators and 
researchers.  
There are several sources of human exposure to PCBs, including food, drinking 
water and air. Oral exposure to PCBs is the predominant route because PCB congeners 
are lipophilic and they can bioaccumulate in the food chain. It is currently assumed that 
the general population is exposed to PCBs mainly through food intake, including 
ingestion of fatty fish, beef, dairy products, and also postnatal breast milk. Two well–
known examples of accidental intake of highly PCB contaminated rice oil are Yusho in 
Japan in 1968 and Yu-Cheng in Taiwan in 1979 [101]. Other populations that may have 
higher PCB contamination include traditionally fish-eating communities [102-104]. 
People who work in PCB-disposal facilities or PCB-contaminated buildings, as well as 
those living in close proximity to former PCB-manufacturing plants, such as the 
Monsanto plant in Anniston, AL, and on the upper Hudson River, NY may also be 
subject to high exposures [105, 106]. In addition, infants are at higher risk of exposure 
than aldults because PCBs bioaccumulate in milk.  
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1.4.2. Mechanisms of PCB toxicity 
PCBs have been demonstranted to cause diverse and sever health effects. 
Theoretically, PCBs consist of 209 congeners, of which only about 130 congeners have 
been identified in commercial products [107] (Fig. 1.3A). Each of the congeners has a 
different toxic level and health effect on the human body. The toxic diversity complicates 
exposure assessment and reduces the validity of statements made about PCBs in general. 
Animal studies revealed that the toxic effects of PCBs can result in cancer and a number 
of non-cancer problems, such as the effects on disruption of the immune system, 
reproductive system, nervous system, and endocrine system [108]. The various health 
effects caused by PCBs may be dependent on each other in such a way that interruption 
in one of those systems by PCBs may extensively relates to other regulatory systems of 
human body. 
Different PCB congeners exhibit their toxicity in different manners [109]. PCBs 
can be categorized into different groups according to their inductive effects to various 
cytochrome P450 (CYP) isoenzymes. The pattern of CYP enzyme induction is largely 
dependent on the degree of planarity of the biphenyl rings, which is determined by the 
position of the chlorines, especially by the number of ortho chlorines that generate steric 
force to the rotation of the rings. The toxicity of coplanar PCB congeners depends on the 
activation of  an intracellular receptor known as aryl hydrocarbon receptor (AhR). AhR is 
a ligand-activated transcription factor that belongs to the steroid-hormone receptor 
family. However, AhR has no recognized endogenous ligand, but only exogenous 
aromatic compounds such as certain polycyclic aromatic compounds and halogenated 
aromatic compounds like the dioxins. Activation of AhR by coplanar PCBs such as 
PCB77, PCB126, and PCB 169 results in the expression of cytochrome P450 1A1, 1A2, 
2A1, and 1B1 genes. Expression of these genes has been demonstrated to result in the 
proliferation of endoplasmic reticulum in the liver; this leads to the alteration of liver 
functions in many aspects, including the perturbation of endocrine function. The second 
group of PCBs consisting of the mono-ortho and some di-ortho components, so called 
“mixed” congeners, keeps most of the coplanar feature of the rings, which enables 
binding to the AhR with intermediate affinity and induces the enzyme expression of CYP 
1A, CYP 1B, and CYP 2B. PCB105, PCB118, PCB138, and PCB 156 belong to this 
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group. The third category is composed of congeners having di-ortho chlorines with one 
or more ortho positions chlorinated on both phenyl rings, for example , PCB99 and 
PCB153 (Fig 1.3B). These are non-coplanar PCB congeners, which barely have binding 
affinity to the AhR and preferentially induce the expression of CYP 2B instead of CYP 
1A. PCB congeners in this group show a variety of toxic effects, including carcinogenesis 
and neurotoxicity, which are different from that of the coplanar PCBs [110]. 
Additionally, some ortho-substituted congeners without AhR binding activity have a 
totally different profile of toxic effects that are unrelated to any CYP enzymes. Several 
studies reported that such PCBs can change the homeostasis of the cells of the nervous 
[111-113] and immune systems [114, 115], and cause a relatively rapid cell death 
resulting from disruption of the membrane stucture, an effect which has not been detected 
in coplanar PCBs at similar concenrations. These PCB congeners can also disrupt the 
release of insulin, decrease the synthesis of dopamine, and activate neurophils to produce 
ROS in neurons [116].  
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Figure 1.3. Chemical structure of the PCB molecule. (A) A biphenyl molecule showing 
chlorine substitution (n=0-5). (B) A specific structure of PCB153 (2,2’,4,4’,5,5’-
hexachlorobiphenyl). 
  
A 
B 
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1.4.3. Neurotoxicity of PCBs 
Exposure to PCBs may result in impairment of both adult neurologic functions 
and early childhood development. For instance, epidemiological and clinical evaluations 
of individuals in the Yusho and Yu Cheng incidents indicate the potential neurotoxic 
effects of PCBs [117]. Exposure to PCBs during the early development of children is also 
linked to decrements in learning [118-121]. On the other hand, experimental studies 
indicate that PCBs have neurotoxic effects on rodents and primates. In laboratory rodents, 
the most significant neurological effects of exposure to PCBs have been detected as 
changes in locomotor activity [122, 123] and altered dopamine function [124, 125]. 
Recent studies demonstrated that exposure to PCBs is associated with central nervous 
system disease, such as Parkinson’s disease (PD), amyotrophic lateral sclerosis, non–
Alzheimer-related dementia, and brain cancer in adults [126-128]. Exposure to PCBs is 
also considered as one of the risk factors for a stroke. For example, recent epidemiologic 
and laboratory data suggest that exposure to PCBs is associated with increased risk 
factors for stroke, such as diabetes, hypertension and vascular disease [108, 129-131]. 
Specifically, it has been demonstrated in the residents in Anniston, AL, that there is a 
significant association between serum PCB concentrations and the prevalence of 
hypertension. [132]. In addition, it has been reported that living close to hazardous waste 
sites contaminated with PCBs is highly linked to increased stroke incidence [14]. 
However, so far there is a general lack of studies to address the influence of PCBs on the 
stroke outcomes and the mechanisms involved in PCB-induced stroke.  
The neurotoxicity of PCBs is likely due to their ability of accumulating in the 
brain tissue. Since PCBs are highly lipophilic, they tend to accumulate in the lipid-rich 
tissue, such as brains, which contain high lipid content. The highest level of PCBs in the 
brain was detected in dead polar sea gulls from the islands of Svalbard, which ranges 
from 3 μmol/kg to 90 μmol/kg [133]; whereas, the PCB brain level in the live glaucous 
gulls was 1.5–30 μmol/kg [134]. In experimental conditions, chronic exposure to PCB 
mixture [126] and acute exposure to individual PCB congeners [135] both resulted in 
detectable PCB levels in animal brains.  
Although the mechanisms have not been clearly elucidated, endothelial activation 
has been implicated as a result of PCB-induced vascular dysfunction [136, 137]. The 
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vascular endothelial cells, which function as a selective barrier between blood and the 
vessel walls, may be targeted by various environmental toxicants, such as PCBs [138]. 
The most widely studied mechanism of PCB-induced endothelial dysfunction was 
focusing on coplanar PCBs [136], because the AhR signaling pathway is also expressed 
in the vasculature [139], and endothelial cells show an induction of CYP1A1 following 
exposure to AhR agonists [140]. Later it was reported that ortho-substituted non-coplanar 
PCBs, for example, PCB104, can also induce endothelial toxicity [141, 142]. Since the 
BBB is mainly composed of endothelial cells, the dysfunction of brain endothelium may 
impair the intact brain environment, and thus influence the neuronal homeostasis and 
induce neurotoxicity. Results published in our laboratory suggested that PCB153, the 
most abundant non-coplanar PCB congener in the environment, can activate the human 
brain endothelial cells by over expression of VCAM-1 and ICAM-1 through NADPH 
oxidase and lipid raft-associated redox signaling pathway [143]. Furthermore, we also 
demonstrated a differentially altered expression of the TJ proteins in brain capillaries as 
well as disrupted function of blood-brain barrier in mice that were acutely exposed to 
three different PCB congeners, including coplanar PCB126, mono-ortho-substituted 
PCB118, and non-coplanar PCB153 [144].  
 
1.5. Nanoparticles 
1.5.1. Overview 
Nanosized particles exist widely in the environment, for example, the products of 
photochemical and volcanic activity. Humans have experienced the exposure to 
nanosized particles throughout their evolutionary phases; however, such exposure has 
increased dramatically in the past century because of anthropogenic causes, such as 
thermo-degradation, internal combustion engines, and power plants. In addition, due to 
the rapidly development of nanotechnology, engineered nanoparticles are likely to 
become another source for human exposure.  
Ambient particulate matter (PM) can be characterized into three categories 
according to their sizes: coarse particles with an aerodynamic diameter in between 2.5 
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μm and 10 μm, fine particles with the diameter of less than 2.5 μm, and ultrafine particles 
(UFPs) of less than 100 nm [145]. Although UFPs are particles in the same size range as 
engineered nanoparticles, they come from different origins and are either produced from 
everyday life, or released as industrial byproducts. Thus, nanometer-scaled particles can 
be roughly divided into three categories: 1) naturally occurring UFPs; 2) inadvertently 
produced by human activity, which also can be named as anthropogenic UFPs; and 3) 
engineered nanoparticles that are deliberately produced for specific purposes [146].  
 
1.5.2. Applications of nanotechnology 
According to the United States Nanotechnology Initiative, nanotechnology is “the 
understanding and control of matter at dimensions of roughly 1–100 nanometers, where 
unique phenomena enable novel applications.” Indeed, nanotechnology has been 
increasingly applied to industrial purposes in the last decade, including cosmetics, 
electronics, aerospace and computer industry. Additionally, given the pressing needs of 
developing new medicines, engineered nanoparicles have been used in medical fields, 
such as biomarkers, diagnostics, and drug delivery.  
 
1.5.3. Toxicity of nanoparticles  
The key properties that have emerged as determinants of cellular uptake, 
subcellular localization, and cytotoxicity of nanoparticles include size, shape, chemical 
composition and surface modification. It has been shown that a significant amount of 
nanoparticles (1-100 nm) are deposited in regions of the respiratory tract, with 20 nm 
nanoparticles having the highest deposition efficiency (~50%) in the region of alveolar 
[147]. In addition to the particle size, the surface characteristics of the nanoparticles can 
result in specific binding interactions, such as receptor-mediated endocytosis, as well as 
nonspecific binding interactions with the cellular membrane [148]. Once deposited, 
nanoparticles tend to translocate to the extrapulmonary sites, circulate with the blood and 
reach other organs through various mechanisms. One of the well-recognized mechanisms 
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involves transcytosis of nanoparticles, which cross epithelia of the respiratory tract into 
the gastrointestinal tract and access the blood circulation directly or via lymphatics, 
resulting in distribution of nanoparticles throughout the body. Deposited nanoparticles 
have also been shown to reach the CNS through the sensory nerves that are embedded in 
the airway epithelia [149] and/or BBB [150, 151]. Studies focusing on nanotoxicity 
suggest that nanoparticles are capable of entering the human body and exhibiting toxic 
effects at the cellular levels [152, 153]. Different surface coatings of nanoparticles lead to 
different cellular toxic levels.  For instance, cationic polystyrene nanospheres increase the 
cytotoxicity in vitro and pulmonary toxicity in vivo as compared with anionic and neutral 
ones [154]. Specific cytotoxicity of silica, which is generally accepted as inert 
nanomaterial, is strongly associated with the presence of surface oxygen radicals and 
ROS [155]. Because of the small size and high surface area of nanoparticles, they can 
easily bind to and hence facilitate the transport of environmental pollutants, which may 
result in efficient delivery of these toxicants into the human body. Air born particles, 
usually considered as efficient carriers for various pollutants from the ambient air, have 
been linked to asthma and cardiovascular dysfunction [156], as well as neurodegenerative 
diseases [157]. 
 
1.5.3.1. Cardiopulmonary toxicity of nanoparticles 
One of the major target organs of nanoparticles and ambient PM is the lung. The 
special characteristics of fine and ultrafine particles, including size, surface area, and 
chemical composition, are all related to the health risks of exposure to PM. It has already 
been reported that elevated ambient air pollution is associated with adverse health effects 
in children, vulnerable adults and patients with asthma [158]. According to recent studies, 
exposure to ambient air pollution can cause decreased lung function, increased 
respiratory infections, and chronic obstructive pulmonary disease (COPD), resulting in 
increased hospitalization and even mortality [159-162].  
On the other hand, increased cardiovascular mortality caused by ambient air 
pollution has also been reported in numerous epidemiologic investigations [163, 164]. In 
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addition to the epidemiology studies, the pathophysiologic evidence documented the 
relationship between particulate air pollution and cardiovascular diseases, such as 
pulmonary and systemic inflammation, accelerated atherosclerosis, and altered cardiac 
autonomic function [165]. A 16-year follow-up study of 500,000 adults reported that 
every 10 μg/m3 elevation of PM2.5 was linked to an 8–18% increase in mortality, which 
resulted from ischemic heart disease, dysrhythmias, heart failure, and cardiac arrest [166]. 
There are three mechanisms that have been proposed to explicate the 
cardiopulmonary morbidity and mortality caused by fine and ultrafine PM [156]. The 
first hypothesis is that the ultrafine or fine PM reaching the lung can stimulate the 
neurons in the lung, influencing CNS and cardiovascular autonomic function. The second 
hypothesizes that fine PM can enter directly into the systemic circulation and translocate 
to target organs, thus initiating inflammatory responses, secreting cytokines, reactive 
oxygen species (ROS), and C-reactive proteins, thereby inducing cardiac dysfunctions. 
The third mechanism proposes that fine PM induces lung injury via oxidative stress, 
which results in increased synthesis of proinflammatory proteins. These events then 
trigger the activation of mitogen-activating protein kinase (MAPK), redox-sensitive 
transcription factors, nuclear factor kappa B (NF-κB), and activating protein-1 (AP-1), 
thereby further enhancing the inflammation in the lung, and leading to cardiac events. 
Inflammation is strongly associated with atherosclerosis. In fact, it has already been 
reported that genetically susceptible mice exposed to ambient air PM chronically exhibit 
acceleration of vascular inflammation and atherosclerosis [167]. Furthermore, human 
studies also support the link of inflammation-induced developments of atherosclerosis 
after exposure to ambient air PM [168].  
 
1.5.3.2. Neurotoxicity of nanoparticles 
It is estimated that in the United States 29 million people are exposed to PM10, 
and 88 million are exposed to PM2.5; whereas, exposure level of UFPs, although 
estimated to be high, are unmonitored and unregulated in the U.S. It is well-recognized 
that PM can induce adverse health effects through the cardiovascular and respiratory 
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systems, while their deleterious consequences on human brains have only lately been 
investigated. PM has been suggested to potentially affect CNS diseases, including 
Alzheimer’s disease (AD), PD, and stroke. A recent study reported that individuals living 
in highly polluted areas showed elevated proinflammatory responses in the brain, 
endothelial cell activation, BBB damage, and brain lesions. More important, increased 
amyloid beta deposition, a hallmark protein of AD, was also detected in the brain tissue 
from studied individuals [169]. In addition, although data is limited, exposure to different 
air pollutants, including PM, is epidemiologically related to increased risk for cerebral 
ischemic events [148, 154, 170] .  
As mentioned above, nano-sized particles can translocate to the brain via 
olfactory nerves and/or BBB. It has been demonstrated in animal models that intranasally 
instilled or inhaled nanoparticles are able to migrate to the olfactory nerves and olfactory 
bulb, or are taken up into the brain directly through trans-synaptic transport [171]. The 
transportation of nanoparticles across the BBB is also possible, which can be mediated 
either by passive diffusion or endocytosis [155].  The ability of nanoparticles to cross the 
BBB and accumulate in a different region of brain [172] may be beneficial for drug 
delivery; however, it also raises the concern of cellular toxic effects that are imposed by 
these nanoparticles. For instance, data published recently suggest that exposure to 
nanoparticles results in damage on neurons [173] and microglia [174], CNS oxidative 
stress [175], neuroinflammation [176], BBB alterations, and cerebrovascular damage 
[145]. The interactions between nanoparticles and/or PM and brain endothelium have 
also been investigated. Results published from our laboratory show that exposure to 
manufactured alumina nanoparticles induces damage on human microvascular 
endothelial cells and BBB disruption through alteration of mitochondrial potential, 
elevation of oxidative stress, and decrease of TJ protein expression [177]. Additionally, 
one study using capillaries extracted from rat brains reported that exposure to particulate 
matter can cause increased generation of ROS and cytokines, which subsequently 
changes the expression and function of transporters, such as P-glycoprotein and 
Multidrug Resistance Associated Protein-2 [178]. More important, ultrafine PM 
deposition was observed in the human brain after long-term exposure to air pollution, 
which is also associated with endothelial cell damage and increase in ICAM and VCAM 
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expression in cerebral vasculature [169]. Therefore, cerebral capillaries may recognize 
and respond to nano-sized particles by producing proinflammatory signals, modulating 
oxidative stress, and regulating physical and chemical barrier function, ultimately leading 
to nanoparticles accessing the brain parenchyma and further contributing to CNS 
pathology.  
 
1.6. Toll-like receptor 4 (TLR4) 
1.6.1. Overview 
Toll-like receptors (TLRs) are pattern-recognition receptors, which play a pivotal 
role in the innate immune response by recognizing and responding to invading pathogens 
[179]. To date, 11 human and 13 mouse TLRs have been identified in both immune and 
non-immune cells [180]. TLRs can be categorized into 3 types according to the specific 
pathogen-associated molecular patterns (PAMPs) they recognize. The first group 
recognizing forms of lipids includes TLR1, TLR2, TLR4 and TLR6. The second group of 
TLRs, which are activated in response to protein ligation, is composed of TLR5 and 
TLR11. TLRs in the third group are localized in the endosomes, an ideal position where 
nucleic acids of bacterial and viral origin can easily access to. This group consists of 
TLR3, TLR7, TLR8 and TLR9. However, the ligands for TLR10, TLR12 and TLR13 
have not been identified yet [180]. In recent years, a growing body of evidence indicates 
that TLRs may recognize endogenous ligands that are released from damaged tissues 
following ischemia/reperfusion injuries, such as those in stroke [181], and mediate the 
immunologic response in noninfectious cells. During stroke-induced tissue injury, 
components of extracellular matrix undergo cleavage by enzymes such as MMPs, 
revealing moieties that may activate TLRs and then initiate TLR-mediated signal 
transduction. The endogenous ligands of TLRs include fibrinogen [182], fibronectin 
[183], low-molecular-weight hyaluronic acid (HA) [184], and heparin sulfate 
proteoglycans [185].  
Upon activation, TLRs can form either homodimers or heterodimers with other 
TLRs and initiate the signaling pathway by recruiting numerous accessory proteins. TLR-
27 
 
activated signaling pathways are generally classified into two categories: myeloid 
differentiation factor 88 (MyD88)-dependent and -independent pathways. Recruitment of 
MyD88 is the universal event of all TLR activation, except for TLR3 [186, 187].  
 
1.6.2. Toll-like receptor 4 (TLR4) signaling  
It is well-known that the exogenous ligand of TLR4 is endotoxin such as 
lipopolysaccharide (LPS), which is an outer membrane component of gram-negative 
bacteria [188]. The activation of TLR4 is complex and involves two principle auxiliary 
proteins, LPS-binding protein (LBP) and cluster differentiation antigen 14 (CD14), as 
well as a coreceptor, myeloid differentiation protein (MD-2) [189]. It has been described 
that MD-2, but not TLR4, directly binds to the conserved component of endotoxin --
amphipathic lipid A [190, 191]. The interaction between the acyl chains of lipid A and 
MD-2 is crucial for the heterodimerization of MD-2 and TLR4, which is required for the 
activation of TLR4 signaling cascade [192, 193]. Among all the TLRs, TLR4 is the only 
one that is capable of signaling through both MyD88-dependent and –independent 
pathways [179, 194]. After TLR4 activation, MyD88-dependent pathway induces 
production of proinflammatory cytokines, including TNFα and IL-1β via activation of 
NF-κB; while MyD88-independent pathway culminates in interferon activation via IRF3 
(interferon regulatory factor) [195]. MAPK signaling can be induced in both MyD88-
dependent and independent pathways, leading to phosphorylation and activation of the 
transcription factor AP-1 [196]. The activation of TLR4 provokes fast and robust host 
immune responses. Endotoxin recognition by TLR4 can initiate a rapid production of 
cytokines, which facilitates the recruitment of inflammatory cells to the infection site 
[197].  
1.6.3. TLR4 and stroke 
The role of TLR4 in stroke has been increasingly recognized. For example, 
mRNA level of TLR4 was upregulated following cerebral ischemia in mouse neurons 
[198, 199]. Furthermore, the brain edema and the infarct volume in mice with TLR4 
deficiency were reduced as compared to wild-type animals after cerebral focal ischemia 
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injury. In addition, TLR4-deficient mice subjected to experimental stroke models 
exhibited improved neurological behavior and decreased levels of proinflammatory 
cytokines in the serum [199-201]. Results from a recent study indicated that the lower 
infarct volume and moderate neurological deficits of TLR4-deficient mice are associated 
with reduced expression of deleterious mediators, such as iNOS and COX2, that induced 
by stroke. Additionally, the expression of MMP9, which plays a role in the cleavage of 
extracellular matrix and contributes to brain damage, was also decreased in TLR4-
deficient animals following cerebral ischemia [202, 203]. Altogether, these studies 
indicate the importance of TLR4 signaling in modulating the outcomes of ischemia-
induced brain damage and suggest that TLR4 may be a target for ischemic stroke therapy 
in the future.  
 
1.6.4. TLR4 and environmental pollutants 
TLR4 is considered as a candidate involved in the susceptibility of toxicity of air 
pollution. For instance, a genomewide linkage analysis identified TLR4 as one of the 
candidate genes for ozone-induced hyperpermeability [204]. A study showed that 
exposure to ozone increased the expression of TLR4 on lung macrophages; additionally, 
TLR4-deficient mice were partially protected from airway hyperresponsiveness (AHR) 
following ozone exposure [205]. In addition, chronic exposure to fine PM induced a 
systemic inflammatory response via TLR4/NADPH oxidase-dependent mechanisms 
[206]. It has also been suggested that cigarette smoke can activate the intracellular 
molecules, including MAPKs, IL-8, and MMP-1, via TLR4 signaling pathway [207]. 
Therefore, it appears that in addition to endotoxin, other environmental pollutants may 
also have a potential to activate TLR4 signaling through a non-classical TLR4 
recognition. 
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2. General hypothesis and specific aims 
Disruption of the BBB is associated with a number of acute and chronic disorders 
of the CNS, such as stroke. Additionally, the integrity of BBB can be affected by various 
endogenous and exogenous factors.  
With the knowledge that individuals with short telomeres are prone to the 
development of neurodegenerative diseases, our first hypothesis of this dissertation is that 
the modulation of telomerase enzyme activity can influence the progression of stroke 
outcomes. To study this hypothesis, the following specific aim was proposed: 
Specific aim 1: To study the hypothesis that deficiency of telomerase activity aggravates 
stroke outcomes through disruption of the blood–brain barrier and potentiation of 
neuroinflammatory responses. 
PCBs and nanoparticles are external factors which contribute to the modification 
of BBB function. However, the cerebrovascular toxicity of PCBs assembled onto 
nanoparticles is unknown. We have selected PCB153 as an example of highly chlorinated 
non-coplanar PCBs and hypothesized that exposure to PCB153 assembled onto 
nanoparticles contributes to the development of stroke by disruption of the integrity of 
the cerebral endothelium through stimulation of toll-like receptor 4 (TLR4) and induction 
of proinflammatory signaling pathways. To test this hypothesis, two specific aims were 
proposed:  
Specific aim 2: To study the hypothesis that binding PCB153 to nanoparticles potentiates 
vascular toxicity and brain damage in an experimental stroke model. 
Specific aim 3: To study the hypothesis that enhanced brain injury induced by PCB153 
bound to nanoparticles is mediated by activation of TLR4, stimulation of inflammatory 
responses, and alterations of tight junction protein expression in brain capillaries. 
 
 
Copyright © Bei Zhang 2013 
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Chapter two: Deficiency of telomerase activity aggravates the blood-brain barrier 
disruption and neuroinflammatory responses in a model of experimental stroke 
This part is published in J Neurosci Res. 2010 Oct; 88(13):2859-68; Copyright © 
2010 Wiley-Liss, Inc, with Bei Zhang as first author. 
 
1. Synopsis 
Epidemiology and genetic studies indicate that patients with telomere length 
shorter than average are at higher risk of dying from heart disease or stroke. Telomeres 
are located at the ends of eukaryotic chromosomes which demonstrate progressive length 
reduction in most somatic cells during aging. The enzyme telomerase can compensate for 
telomere loss during cell replication. The present study is aimed to investigate the 
contribution of telomerase to stroke and the blood-brain barrier (BBB) dysfunction. 
Telomerase reverse transcriptase knock-out (TERT −/−) mice and littermate controls with 
normal TERT expression were subjected to a 24 h permanent middle cerebral artery 
occlusion (pMCAO). The stroke outcomes were assessed in terms of neurological scores 
and infarct volumes. In addition, we evaluated oxidative stress, permeability across the 
BBB, and the integrity of tight junctions in brain microvessels. Neurological testing 
revealed that TERT −/− mice showed enhanced deficits as compared to controls. These 
changes were associated with a greater infarct volume. The expression of tight junction 
protein ZO-1 decreased markedly in ischemic hemispheres of TERT −/− mice. The brain 
microvessels of TERT −/− mice also were more susceptible to oxidative stress, revealing 
higher superoxide and lower glutathione levels as compared to mice with normal TERT 
expression. Importantly, TERT deficiency potentiated the production of inflammatory 
mediators, such as TNF-alpha, IL-1beta and ICAM-1 in the ischemic hemispheres of 
mice with pMCAO. Our study suggests that TERT deficiency can predispose to the 
development of stroke in an experimental model of this disease. 
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2. Introduction 
Telomeres are located at the ends of eukaryotic chromosomes and protect these 
regions from degradation. Telomerase reverse transcriptase (TERT) is the catalytic 
subunit of telomerase that is required for the synthesis of new telomeric DNA repeats in 
dividing cells [208]. Telomerase activity is down-regulated before birth and remains at 
very low or undetectable levels in most human somatic tissues [77]. However, a growing 
body of evidence suggests that TERT expression in adult brain may be induced as the 
result of metabolic stress, such as hypoxia or brain ischemia, in astrocytes, microglia, 
vascular smooth muscles, and cortical neurons [86, 209-211]. For example, TERT 
transgenic mice show a reduced myocardial infarct area after coronary artery ligation, 
and exogenous TERT expression in cardiac myocytes can prevent apoptosis and promote 
survival [212]. 
The blood-brain barrier (BBB) is a physical and metabolic barrier separating the 
microenvironment of the central nervous system (CNS) from the peripheral circulation. 
The BBB is mainly composed of brain endothelial cells connected by tight junctions 
(TJs), which are maintained by transmembrane TJ proteins, such as occludin, claudins 
and junctional adhesion molecules (JAMs) [213]. Moreover, cytoplasmic scaffolding 
proteins, such as zonula occludens (ZO) proteins, anchor the integral transmembrane 
proteins to actin cytoskeleton. Under ischemic stroke conditions, depletion of blood flow 
leads to the BBB disruption and increased paracellular permeability across cerebral 
vessels [214]. Activated brain microvascular endothelium in response to environmental 
stress can exhibit increased cellular oxidative stress, activation of redox-sensitive 
transcription factors, and production of inflammatory molecules [215]. Ischemia is a 
potent inducer of cytokines, such as interleukin-1β (IL-1β), tumor necrosis factor-α 
(TNF-α), and adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1). 
The function of telomerase in the injured and ischemic brain has not been clearly 
defined. Therefore, the aim of our present study is to explore the influence of TERT 
deletion on the BBB integrity and brain inflammatory responses in the context of 
ischemic brain injury. Our study provides evidence that TERT deficiency potentiates 
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ischemia-induced neurological deficits, tissue injury, and BBB dysfunction as compared 
to control mice with normal TERT expression. 
 
3. Materials and methods 
TERT deficient mice and the model of the permanent middle cerebral artery 
occlusion (pMCAO) 
All experiments were performed following the protocol approved by the 
Institutional Animal Care and Use Committee in strict accordance with the National 
Institutes of Health guidelines. The focal ischemia model employed in the present study 
was based on a permanent occlusion of the middle cerebral artery (MCA) as described 
earlier [216]. Sham animals were operated upon with only ligation of the left CCA, 
without blocking the MCA. The severity of neurological deficit was evaluated according 
to the modified scale by Wauquier et al [217] (Table 2.1). 
The experimental animals (4-month-old male mice) were divided into four groups: 
wild-type mice subjected to pMCAO, wild-type sham-operated mice; TERT −/− mice 
subjected to pMCAO, and TERT −/− sham-operated mice. TERT −/− mice were 
generated on the C57BL/6J genetic background and bred through heterozygous mating 
[218]. Littermate mice with normal TERT expression were used as the control group. 
 
Evaluation of cerebral infarct volume 
The infarct volume was assessed 24 h post induction of pMCAO using staining 
with 2% 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma) [219] and quantified with 
NIH Image-J software. The infarct volume (mm3) was determined as a percentage 
volume of the whole brain according to the formula: Infarct volume (%) = 100×[(Vc-
Vi)/2Vc]; where Vc is the total volume of the contralateral hemisphere, and Vi is the 
noninfarcted volume of the ipsilateral hemisphere. 
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Western blotting 
Each mouse brain was divided into two parts: contralateral (non-ischemic) 
hemisphere and ipsilateral (ischemic) hemisphere. The cortical gray matter was isolated 
and homogenized with RIPA lysis buffer (Santa Cruz, CA). The samples were then 
centrifuged at 15,000 × g for 15 min at 4°C. The supernatants were collected and protein 
concentrations were determined using BCA protein assay kit (Pierce, Rockford, IL). 
Samples were separated on 4–15% Tris-HCl Ready SDS-polyacrylamide gels (Bio-Rad 
Laboratories, Hercules, CA), transferred onto PVDF membrane (Bio-Rad Laboratories), 
and incubated with the respective antibodies. Anti-ZO-1 (1:1000 dilution), anti-ZO-2 
(1:500 dilution), anti-occludin (1:1000 dilution), anti-JAM-A (1:500 dilution), anti-
claudin-1(1:500 dilution), and anti-claudin-5 (1:500 dilution) antibodies were purchased 
from Zymed (San Francisco, CA). Anti-actin antibody (1:2500 dilution) was purchased 
from Sigma, and all secondary antibodies were from Santa Cruz Biotechnology. For 
visualization of detected proteins, immunoblots were analyzed using an ECL Western 
blot detection kit (Amersham Biosciences, Piscataway, NJ). Quantification of 
immunoreactive bands was performed by scanning densitometry using UN-SCAN-IT gel 
image analysis software (Silk Scientific, Orem, UT). 
 
Real-Time RT-PCR 
Real-time reverse transcriptase–polymerase chain reaction (RT-PCR) was 
performed as described previously [220]. Briefly, cortical grey matter samples were 
weighed and homogenized in 1 ml of TRIZOL reagent (Invitrogen, Carlsbad, CA) per 50 
mg of tissue. Total RNA was extracted according to the manufacturer’s protocol with an 
additional chloroform extraction and phase separation as well as an additional wash of 
the isolated RNA in 70% ethanol. Then, 1 µg of RNA was reverse-transcribed using the 
Reverse Transcription System (Promega, Madison, WI) in a total volume of 20 µL with 
random hexamer primers. The following conditions were employed for reverse 
transcription: 25°C for 10 min, 48°C for 30 min, and 95°C for 5 min. PCR amplification 
was performed using 3 µL of RT product, Taqman Universal PCR Master Mix (Applied 
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Biosystems, Foster City, CA), and predeveloped primer pairs and Taqman probes 
(Applied Biosystems) in a total volume of 25 µL. The following thermocycling 
conditions were employed: 95°C for 10 min, followed by 95°C for 15 sec, and 60°C for 
60 sec (for up to 40 cycles). Expression of mRNA was calculated and analyzed by the 
comparative CT method as described [221]. PCR amplification of mouse actin mRNA (a 
housekeeping gene) was performed for each sample to normalize mRNA levels of the 
target genes. 
 
Measurements of glutathione (GSH) and superoxide levels 
GSH content was determined by monochlorobimane (MCB; Invitrogen) staining. 
MCB conjugates with GSH through a reaction catalyzed by glutathione-S-transferase 
(GST) to form a fluorescent stable adduct (MCB-GSH) [222]. The levels of superoxide 
were detected by dihydroethidium (DHE; Invitrogen) staining. DHE is cell permeable, 
and at the presence of superoxide, it is converted to a fluorescent product ethidium 
bromide (EtBR), which then is trapped by intercalating with DNA [223]. Briefly, 
microvessels were incubated with 1 mL MCB solution (100 µM) or 1 mL DHE solution 
(10 µM) at 37°C for 90 min. Fluorescence was assessed using the Olympus BX61W1 
confocal microscope (Olympus Corp., Tokyo, Japan). 
 
Statistical analysis 
Data are expressed as means ± SEM. Statistical analysis was completed by using 
Sigma-Stat 2.03 (SPSS, Chicago, IL, USA). Two-tailed Student’s t-test or one-way 
ANOVA followed by Student-Newman-Keuls post hoc test was used to compare mean 
responses among the treatments. A statistical probability of p < 0.05 was considered 
significant. 
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4. Results 
TERT deficiency increases neurological deficit and infarct volume following 
pMCAO 
As indicated in Figure 2.1, TERT-deficient mice exhibited significantly higher 
neurologic deficits 24 h post inducing pMCAO as compared to mice with normal TERT 
expression. The most affected locomotor functions in TERT −/− mice were the 
parameters listed in category III as listed in Table 2.1. The functional locomotor scores 
were correlated with infarct volume as determined by TTC staining 24 h post the onset of 
pMCAO. As shown in Figure 2.2, the total infarct volume in the TERT −/− mice was 
larger by an approximately 20% as compared to control mice. 
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Table 2.1. Locomotor scale to assess neurological deficit in mice  
 Points Category 
Ipsilateral eyelid closed 1 I. Head and trunk 
Hunched back 1  
Grasping (string) upon lifting the tail 1 II. Limb 
Frontpaw withdrawal upon lifting the tail 1  
Hindpaw withdrawal upon lifting the tail 1  
Circling when walking 1 III. Whole-body activity 
Body leaning to one side 
when placing on the table 
1  
No spontaneous movement 1  
Total score 8  
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Figure 2.1. TERT deficiency potentiates neurological deficits induced by permanent 
occlusion of MCA. Neurological deficit was evaluated 24 hr post-pMCAO by using the 
eight-point score system listed in Table 2.1; n=10. *Significantly different compared with 
mice with normal TERT expression at P < 0.05. 
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Figure 2.2. TERT deficiency increases infarct volume following pMCAO. Brain sections 
were stained with TTC 24 hr post-pMCAO. White areas correspond to damaged brain 
tissue resulting from infarct (A), and quantified results are depicted in the form of bar 
graphs (B); n=6. *Significantly different compared with mice with normal TERT 
expression at P < 0.01. 
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TERT deficiency enhances pMCAO-induced oxidative stress in brain microvessels 
In order to address potential mechanisms of increased infarct volume in TERT 
−/− mice, our studies focused on the involvement of the BBB and induction of oxidative 
stress in brain microvessels. Superoxide levels were detected in isolated brain 
microvessels 24 h post induction of pMCAO (Fig. 2.3). The most pronounced increase in 
superoxide levels was observed in ipsilateral hemispheres of TERT −/− mice with 
induced pMCAO (~4.5 times of control levels). Although superoxide levels were also 
elevated in ipsilateral hemispheres of control mice with pMCAO, these changes were 
approximately 2-fold lower as compared to the corresponding values in TERT −/− 
animals. 
Induction of pMCAO resulted in decreased glutathione levels in ipsilateral 
hemispheres in both control and TERT −/− mice. However, this effect was significantly 
enhanced in TERT-deficient animals, indicating severely diminished antioxidant 
protection in this group of mice. In contrast to control mice, glutathione levels were also 
diminished in contralateral hemispheres in TERT −/− animals (Fig. 2.4). 
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Figure 2.3. pMCAO-induced oxidative stress in brain microvessels is enhanced in 
TERT-deficient mice. Twenty-four hours after pMCAO or sham operation, brain 
microvessels were isolated and stained for superoxide levels with DHE (red). All images 
were acquired with a X60 oil-immersion lens under identical instrument settings. Merged 
micrographs of DHE staining and phase-contrast micrographs localized superoxide 
within the microvessels (A). The intensity of DHE fluorescence was quantified and 
depicted in the form of a bar graph (B). DHE fluorescence values in microvessels from 
ipsilateral and contralateral hemispheres of sham-operated mice were the same and the 
results were pooled; n=6–8. *Significantly different compared with sham operated mice 
at P < 0.05. †Results in the TERT-/- group are statistically different from those in the 
corresponding hemispheres of mice with normal TERT expression at P < 0.05. 
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Figure 2.4. TERT deficiency potentiates pMCAO-induced glutathione depletion in brain 
microvessels. Twenty-four hours after pMCAO or sham operation, brain microvessels 
were isolated and stained for glutathione levels with MCB (blue). Images were acquired 
as for Figure 2.3. Merged micrographs of glutathione staining and phase-contrast 
micrographs localized glutathione within the microvessels (A). The intensity of 
glutathione staining was quantified and depicted in the form of a bar graph (B); n=6–8. 
Fluorescence intensities in microvessels from ipsilateral and contralateral hemispheres of 
sham-operated mice were the same, and the results were pooled. *Significantly different 
compared with sham operated mice at P < 0.05. †Results in the TERT-/- group are 
statistically different from those in the corresponding hemispheres of mice with normal 
TERT expression at P < 0.05. 
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TERT deficiency differentially influences pMCAO-induced changes in TJ protein 
expression  
TJs are the main structural elements of cerebral microvessels that regulate the 
integrity of the BBB. Therefore, we evaluated the effects of TERT deficiency on the 
levels of TJ proteins in mice with pMCAO. As illustrated in Figure 2.5, occludin and ZO-
1 exhibited different expression patterns following MCA occlusion. Occludin expression 
was significantly increased in the ipsilateral hemisphere of control mice with pMCAO; 
however, the level of this TJ protein was not affected in the brains of TERT −/− mice 
with pMCAO as compared to sham controls. In contrast, expression of ZO-1 decreased to 
almost negligible levels in the ipsilateral hemisphere of TERT deficient mice with 
pMCAO. Similar tendency was observed in mice with normal TERT expression; 
however, these changes were significantly less pronounced. Expression of other TJ 
proteins, such as ZO-2, JAM-A, claudin-5, and claudin-1, was not affected 24 h post 
pMCAO in either TERT −/− or control mice (data not shown). 
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Figure 2.5. TERT deficiency differentially influences pMCAO-induced changes in TJ 
protein expression. Expression of TJ proteins occluding (A) and ZO-1 (B) was analyzed 
by Western blotting 24 hr after pMCAO or sham operation separately in ipsilateral 
(ischemic) and contralateral (nonischemic) hemispheres. The blots are representative 
images from four mice per group, and the quantified results are depicted in the form of 
bar graphs; n=4. Significantly different compared with the respective hemispheres of 
sham operated mice at **P < 0.01, ***P < 0.001. Results in the TERT-/- group are 
statistically different from those in the corresponding hemispheres of mice with normal 
TERT expression at †P < 0.05, †††P < 0.001. 
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TERT deficiency potentiates inflammatory responses following pMCAO  
We also examined brain tissues for mRNA expression of TNF-α, IL-1β, and 
ICAM-1 24 h post induction of pMCAO. The choice of these inflammatory mediators 
includes cytokines (TNF-α and IL-1β), and an adhesion molecule (ICAM-1). These 
agents are critical in the induction of inflammatory reactions in the vascular endothelium 
by stimulating leukocyte recruitment, adhesion, and transendothelial migration. pMCAO 
resulted in a significant elevation of mRNA levels of all studied inflammatory mediators 
in ipsilateral hemispheres of TERT −/− and control mice (Fig. 2.6A–C). Importantly, 
these levels were more advanced in TERT deficient mice. Specifically, mRNA levels of 
TNF-α, IL-1β and ICAM-1 in the ischemic hemisphere of TERT −/− mice increased 3, 
2.6, and 2.4-fold, respectively, as compared to the corresponding hemisphere of control 
mice with pMCAO. TNF-α and ICAM-1 mRNA expression was also elevated in 
contralateral hemispheres of TERT −/− mice. 
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Figure 2.6. TERT deficiency potentiates pMCAO-induced inflammatory responses. 
Experiments were performed as described for Figure 2.5. mRNA levels of TNF-α (A), 
IL-1β (B), and ICAM-1 (C) were determined by real-time PCR; n=4. Significantly 
different compared with the corresponding hemispheres of sham operated animals at *P < 
0.05, ***P < 0.001. Results in the TERT-/- group are statistically different from those in 
the corresponding hemispheres of mice with normal TERT expression at †P < 0.05, ††P 
< 0.01, †††P < 0.001. 
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5. Discussion 
The BBB is a dynamic interface between the peripheral circulation and the CNS. 
In the present study, we provide in vivo evidence for the role of TERT deficiency in the 
BBB dysfunction and brain injury during ischemic stroke. Specifically, TERT −/− mice 
showed severe neurological deficits and increased infarct volume as compared to animals 
with normal TERT expression 24 h post induction of pMCAO. These alterations were 
closely associated with increased oxidative stress in brain capillaries, alterations of TJ 
protein expression and increased inflammatory responses. 
The presence of telomerase activity in the brain during development characterizes 
the role of this enzyme in neuronal differentiation and survival [224]. Both telomerase 
and TERT levels are generally decreased during embryonic and early postnatal 
development in somatic cells. Particularly, telomerase activity is reduced as proliferation 
of neuroblasts is decreased, whereas TERT levels are reduced in conjunction with 
neuronal differentiation and natural cell death [83]. This dissociation between telomerase 
activity and TERT levels suggests that TERT may function to promote cell survival 
through a mechanism other than maintaining telomere length [225]. In addition, recent 
reports from epidemiological and genetic studies indicate that humans with shorter 
telomeres than average are at higher risk of heart disease, stroke and degenerative 
diseases [77]. 
Our study indicated that TERT −/− mice are more susceptible to ischemic brain 
injury. To support these observations, it was recently reported that TERT transgenic mice 
were characterized by significantly reduced infarct volume after MCAO and protective 
effects against NMDA-induced neurotoxicity [86]. In addition, TERT transgenic mice 
exhibited a reduced myocardial infarct area after coronary artery ligation, and exogenous 
TERT expression in cardiac myocytes promoted survival by protection against apoptosis 
[212]. 
Impairment of TJs and the accompanied dysfunction of the BBB are typical 
events during cerebral ischemia [226]. Indeed, our studies indicated a marked loss of ZO-
1 in the ipsilateral hemisphere of the mice with pMCAO. Importantly, this effect was 
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potentiated in TERT −/− mice as compared to control animals. ZO-1 is essential for TJ 
assembly [227] as it forms a scaffold complex with other cytosolic accessory proteins, 
such as ZO-2 and AF6, to anchor integral membrane proteins to the actin cytoskeleton. 
Disruption of ZO-1 at TJs has been observed in response to cytokines [228] and hypoxia 
[229], and has been correlated with increased transendothelial permeability. In the 
context of stroke, an ex vivo study of cerebral ischemia identified translocation and 
decreased expression of occludin and ZO-1 in brain capillaries after microsphere-induced 
cerebral embolism in rats [230]. In contrast, we observed increased occludin levels in 
control mice following pMCAO but no apparent changes in TERT −/− mice. The 
influence of alterations of occludin expression on the BBB integrity is not fully 
understood. For example, increased occludin levels frequently correspond with decreased 
permeability across the BBB [231]; however, others reported also the opposite 
phenomenon [232]. It appears that interactions of occludin with other TJ proteins, 
including ZO-1, may have more prominent consequences on the BBB integrity than 
changes in levels of this TJ protein. 
The loss of blood supply to the brain associated with the onset of pMCAO results 
in a cascade of events including inflammation and induction of oxidative stress around 
the infarcted region. Inflammatory responses include upregulation of cytokines (e.g. 
TNF-α and IL-1β) [233] which have been shown to precede BBB permeability and 
promote leukocyte infiltration into the brain tissue through induction of adhesion 
molecules on the surface of endothelial cells [234]. In addition, activated microglia can 
release a variety of inflammatory mediators upon brain ischemia, while blood-borne 
leukocytes can migrate into the brain and subsequently contribute to production of 
inflammatory substances, increased permeability of the BBB and secondary injury to the 
brain tissue [41, 235]. Our novel findings illustrate that pMCAO resulted in more 
pronounced expression of TNF-α, IL-1β, and ICAM-1 in TERT deficient mice as 
compared to mice with normal TERT expression. These results are in agreement with the 
report that TNF-α-mediated increase in monocyte adhesion in senescent human 
endothelial cells can be attenuated in TERT transfected cells [236], indicating a relation 
between telomerase activity and endothelial dysfunction. 
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Another novel observation of the present study indicates that superoxide 
production and decreased GSH levels in brain capillaries are more pronounced in TERT 
−/− mice as compared to controls with normal TERT expression upon induction of 
pMCAO. Increased oxidative stress is known to stimulate redox-regulated signaling 
pathways that dysregulate TJ protein expression and affect the BBB integrity [237]. 
Persistent oxidative stress can lead to diminished antioxidant protection [238, 239], as 
observed in the present study by decreased GSH levels in brain microvessels. GSH is a 
critical antioxidant in vascular endothelial cells and its depletion is strongly associated 
with BBB dysfunction [240]. In agreement with our study, recent evidence emphasizes 
the role of telomerase in the protection against induction of oxidative stress. For example, 
overexpression of TERT increased oxidative stress resistance, improved antioxidant 
defense, and differentiation capacity in mouse embryonic stem cells [241]. 
Overexpression of TERT also resulted in improved mitochondrial functions, protecting 
against production of superoxide radicals and increased cellular ROS levels [92]. To 
further demonstrate the interrelationship between oxidative stress and telomerase activity, 
it was demonstrated that cellular oxidation can impair telomerase activity and accelerate 
the telomere shortening in endothelial [242, 243] and vascular smooth muscle cells [244], 
as well as result in telomerase exclusion from the nucleus to the mitochondria [245, 246].  
Increased oxidative stress and diminished antioxidative protection in brain 
microvessels of TERT −/− animals may further contribute to the disruption of the BBB 
integrity as observed in the present study. In fact, it was demonstrated that oxidative 
stress can alter TJs at the BBB level by alterations of phosphorylation and expression of 
TJ proteins [232, 247-249]. Increased levels of ROS can also stimulate NF-κB activation, 
leading to increased production of inflammatory cytokines and adhesion molecules [250], 
such as TNF-α, IL-1β, and ICAM-1 evaluated in the present manuscript. In the present 
study, elevated superoxide levels were mostly limited to the ipsilateral hemisphere 
following the pMCAO-based experimental stroke model. In agreement with these results, 
increased expression of inflammatory genes and disruption of TJ proteins were also 
mostly affected in ipsilateral hemisphere. 
49 
 
In conclusion, the results of the present study indicate that TERT deficiency 
potentiates the BBB dysfunction, inflammatory responses, and oxidative stress associated 
with experimental stroke induced by the permanent occlusion of MCA. Importantly, 
these alterations were associated with increased neurological deficit and infarct volume. 
The present results emphasize the importance of TERT in the protection of brain injury 
against ischemic stroke. 
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Chapter three: Cerebrovascular toxicity of PCB153 is enhanced by binding to silica 
nanoparticles 
This part is published in J Neuroimmune Pharmacol. 2012 Dec; 7(4):991-1001; 
Copyright © 2012 Springer Science+Business Media, with Bei Zhang as first author.  
 
1. Synopsis 
Environmental polychlorinated biphenyls (PCBs) are frequently bound onto 
nanoparticles (NPs). However, the toxicity and health effects of PCBs assembled onto 
nanoparticles are unknown. The aim of this study was to study the hypothesis that 
binding PCBs to silica NPs potentiates PCB-induced cerebrovascular toxicity and brain 
damage in an experimental stroke model. Mice (C57BL/6, males, 12-week-old) were 
exposed to PCB153 bound to NPs (PCB153-NPs), PCB153, or vehicle. PCB153 was 
administered in the amount of 5 ng/g body weight. A group of treated animals was 
subjected to a 40 min ischemia, followed by a 24 h reperfusion. The blood–brain barrier 
(BBB) permeability, brain infarct volume, expression of tight junction (TJ) proteins, and 
inflammatory mediators were assessed. As compared to controls, a 24 h exposure to 
PCB153-NPs injected into cerebral vasculature resulted in significant elevation of the 
BBB permeability, disruption of TJ protein expression, increased proinflammatory 
responses, and enhanced monocyte transmigration in mouse brain capillaries. Importantly, 
exposure to PCB153-NPs increased stroke volume and potentiated brain damage in mice 
subjected to ischemia/reperfusion. A long-term (30 days) oral exposure to PCB153-NPs 
resulted in a higher PCB153 content in the abdominal adipose tissue and amplified 
adhesion of leukocytes to the brain endothelium as compared to treatment with PCB153 
alone. This study provides the first evidence that binding to NPs increases 
cerebrovascular toxicity of environmental toxicants, such as PCB153. 
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2. Introduction 
Polychlorinated biphenyls (PCBs) are organochlorinated chemicals that were 
mass produced for industrial usage in the U.S. for approximately 50 years [251]. 
Environmental exposure to PCBs is ongoing as a result of continued use and disposal of 
products containing these toxicants [252], as well as prevalent bioaccumulation of PCBs 
in the biosphere and in the food chain [253]. PCBs present in the environment can bind to 
organic particles in water, sediments, soil, and atmospheric particulates. In contaminated 
areas in New Bedford Harbor (MA), average PCB concentration was determined to be 
2.3 mg/L in water and 351 μg/kg in sediments [254]. The average PCB levels in the air 
and soil samples collected in Anniston (AL) were 62.8 ng/m3 and 2.8 mg/kg, respectively 
[255]. Importantly, elevated environmental levels of PCBs were associated with 
increased levels in serum in the exposed population and higher prevalence to disease 
development [132, 256]. Evidence suggests that exposure to PCBs may increase the 
incidence of stroke [14] and worsen stroke outcome [257]. Importantly, highly 
chlorinated ortho-PCBs preferentially accumulate in the brain and thus induce prominent 
neurotoxic effects [258]. The most representative compound from this group is 
2,2′,4,4′,5,5′-hexachlorobiphenyl (PCB153), which is common in environmental samples 
and accounts for 15–30 % of total PCB content in most human samples [259].  
When released from environmental sources, PCBs can be adsorbed onto 
suspended particles present in the air, such as ultrafine (nano-size particles) or fine 
particles. It has been reported that PCBs can bind to indoor and outdoor dust with the 
particle size ranging from 0.95 μm to 1.5 μm [260-262]. Nanoparticles (NPs) and fine 
particles are able to penetrate the alveolar-capillary barrier of the lung to access 
circulating blood cells (e.g. erythrocytes) [263]. Results from animal experiments 
indicated that ultrafine particles can translocate into the systemic circulation [264] and 
the brain [149] through inhalation or nasal instillation. Thus, particulate components from 
the ambient air may act as effective carriers for various environmental pollutants entering 
the brain. 
The blood–brain barrier (BBB) is a chemical and physical barrier composed of 
brain endothelial cells, which are connected by tight junctions (TJs), and interact with 
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other cells and basement membrane of the neurovascular units [265, 266]. The presence 
of intact TJs is essential in maintaining a functional BBB [265]. Disruption of the BBB is 
associated with several acute and chronic disorders of the central nervous system (CNS), 
including stroke, ischemia/reperfusion, hypoxia/reoxygenation and cerebrovascular 
dysfunction [52, 266, 267]. In addition, age and conditions linked to aging, including 
hypertension and brain ischemia, can contribute to alterations of BBB functions. The 
BBB contains the specialized carriers for glucose, amino acids, purine bases, nucleosides 
and other substances, which ensure adequate delivery of nutrients, hormones, and 
neurotransmitters. At the same time, the brain endothelium acts as an effective barrier to 
prevent the circulating toxic agents entering the brain parenchyma. Thus, age-related 
BBB dysfunction may impair the transport of nutrients and metabolites to the brain, 
whereas the leaky barrier allows the circulating toxicants access the brain tissue. 
Moreover, genetic variances may affect the BBB functions and contribute to the disease 
etiology. For instance, heterozygous mutation in the glut1 gene results in glucose 
transporter (GLUT-1) deficiency syndrome [268], which impairs the transport of glucose 
across the BBB. The cells composing the BBB can also interact with NPs. It was 
demonstrated that NPs have ability to cross the BBB and accumulate in brain 
parenchyma [169].  
With the robust development of nanotechnology, nanotoxicity is also gaining 
increased attention. Surface modifications of NPs markedly affect their biological and 
toxicological properties. For example, neutral and anionic NPs at low concentrations 
appear to have no effect on BBB integrity, whereas high concentrations of positively or 
negatively-charged NPs disrupted the BBB. Anionic NPs were preferentially taken up by 
the brains as compared to neutral or positively-charged NPs [269]. Other unique 
functionalities of NPs, including high surface area, make NPs a target for other 
environmental contaminants, such as PCBs. Nevertheless, there are no research reports 
on cerebrovascular toxicity of PCBs bound to NPs. In the present study, we demonstrate 
for the first time that such binding results in increased cerebrovascular toxicity of 
PCB153, leading to enhanced brain injury in experimental stroke model. 
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3. Materials and methods 
Characterization of silica NPs and binding PCB153 to NPs 
Silica NPs were purchased from NanoAmor (Houston, TX). In order to determine 
the effect of different media on particle size distribution, particles were dispersed in 
distilled water, phosphate buffered saline (PBS), or EBM-2. Then, the diameter size and 
the polydispersity index (PDI) were assessed by dynamic light scattering (DLS) using a 
Malvern Instruments Zetasizer Nano ZS. 
In order to assemble PCB153 onto NPs, silica NPs (80 mg) were mixed with 10 
mg of PCB153 (2,2′,4,4′,5,5′- hexachlorobiphenyl, AccuStandard, New Haven, CT) in 
acetone and sonicated. Acetone was allowed to evaporate and the mixture of NPs with 
PCB153 was resuspended in water PBS or EBM-2. Sonication was applied during the 
process to minimize the particles’ aggregation. The suspension was centrifuged at 12,000 
rpm for 5 min. The supernatant was collected to analyze the final concentration of 
PCB153 by gas chromatography/mass spectrometry (GC/MS). Control NPs were 
prepared using the same procedure, without adding PCB153. 
 
Animals and experiment groups 
All experiments were performed following the protocol approved by the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice (C57BL/6, 
12-week-old, male) were anesthetized with isoflurane and then infused with: a) PCB153 
bound to silica NPs (PCB153-NPs), b) PCB153 dissolved in 0.01 % DMSO (PCB153), c) 
silica NPs alone, or d) vehicle (DMSO or PBS). Sham controls were subjected to surgical 
procedures without additional treatment. All injections were performed through the 
internal carotid artery (ICA) to ensure drug delivery into the brain. PCB153 was 
administered in the amount of 5 ng/g body weight. This design simplified the routes of 
exposure and potential surface modification of NPs, which may occur when passing the 
gastrointestinal track, skin, or airway passages. Direct injections into the bloodstream 
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allowed for precise dosing to evaluate whether binding of PCB153 to NPs influences 
their toxicological properties.  
In selected experiments, mice were exposed to PCB153-NPs or PCB153 alone by 
oral gavage at the dose of 5 ng/g once a day for 30 days. Such treatment mimics chronic 
exposure to PCBs through food chain. Adipose tissue was then collected and analyzed for 
PCB153 levels. 
 
Surgical procedures 
Injections via the internal carotid artery (ICA) and the installation of the vessel 
port were performed as described earlier by our group [270]. The focal ischemia stroke 
model was based on a 40 min occlusion of the middle cerebral artery (MCA), confirmed 
by a sharp decline in cerebral blood flow, followed by 24 h reperfusion. Then, the brains 
were removed, sectioned into 1 mm slides, and the infarct area was visualized by 2,3,5-
triphenyltetrazolium chloride (TTC) staining. The infarct volume was quantified by 
ImageJ analysis software as described earlier [271].  
Cranial windows were installed to observe leukocyte interactions with cerebral 
vessels. Under anesthesia, the left parietal bone was exposed by a midline skin incision, 
followed by a craniotomy (2.5 mm diameter) 2.5 mm posterior from the bregma and 2.5 
mm lateral from the midline. The dura mater was removed to expose the underlying pial 
vasculature. A glass coverslip was placed and sealed with dental cement over the exposed 
brain tissue, which was suffused with artificial cerebrospinal fluid. Attachment of 
leukocyte to the brain endothelium was assessed as described earlier [272] using 
rhodamine 6G (Rho6G) chloride to label circulating leukocytes. 
 
Monocyte transmigration assay in vivo 
Murine monocyte/macrophage cells J774.1 were cultured in DMEM medium 
(Invitrogen, Carlsbad, CA) supplemented with 10 % FBS and antibiotics (penicillin, 100 
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U/ml; and streptomycin, 100 μg/ml, Invitrogen). Monocytes were labeled with 20 μM 
CFDA-SE (Vybrant CFDA-SE Cell Tracer Kit, Invitrogen), a dye which passively 
diffuses into cells and yields fluorescence when its acetate groups are cleaved by 
intracellular esterases. Mice were injected into the ICA with labeled monocytes at a 
concentration of 0.5×106 cells, which were then allowed to circulate for 24 h. Brains were 
sliced (20 μm thick) and stained to visualize the interaction of labeled monocytes with the 
brain endothelium. Staining for claudin-5 was employed to visualize the brain capillaries. 
Images were acquired using a Nikon fluorescence microscope (Nikon, Melville, NY) 
equipped with a SPOT RT camera and software (Diagnostic Instruments, Sterling 
Heights, MI).  
 
Analysis of PCB153 levels in adipose tissue 
Tissue levels of PCB153 were analyzed as described previously [135]. Briefly, 
adipose tissue samples (0.2–0.5 g) were spiked with surrogate standards (PCB65 and 
PCB166) and mixed with 1.0 g diatomaceous earth. The mixtures were then 
homogenized and extracted with ASE 200 accelerated solvent extractor (Dionex 
Corporation, Sunnyvale, CA). After extraction with hexane, the extracts were 
concentrated using Rotavapor, vortexed thoroughly, left overnight to achieve phase 
separation, and the hexane layer containing PCB153 was collected. The extracted 
aliquots were further concentrated and 10 μL of 1.0 ng/μL of internal standard PCB209 
was added to each sample and transferred to a glass microvial for analysis. Gas 
chromatographic analysis was performed with a GC-μECD system (Agilent GC 6890 N, 
autosampler G2913A, μECD detector) (Agilent Technologies, Santa Clara, CA). PCB153 
was identified on the basis of the retention time relative to standards. Quantification was 
achieved based on calibration curves obtained using PCB standards, the recovery 
efficiency calculated from the surrogates, and the sample weight. 
 
BBB permeability assay 
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Animals were injected i.p. with 200 μL 10 % sodium fluorescein in PBS. Fifteen 
minutes later, blood was collected via cardiac puncture. Animals were transcardially 
perfused with 0.9 % saline, the brains were harvested, and homogenized in PBS (1/10; 
w/v). Fluorescence was determined using excitation at 485 nm and emission at 530 nm. 
The permeability results were presented as a ratio of brain to plasma fluorescence 
intensity. 
 
Immunoblotting and immunoreactivity 
Brain microvessels were isolated as described previously [144] and either lysed 
for immunoblotting or smeared on the glass slides for immunoreactivity assessments. 
Lysed microvessels (50 μg protein per sample) were electrophoresed on 4–15 % Tris–
HCl Ready SDS-polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA), transferred 
onto PVDF membranes (Bio-Rad Laboratories), and incubated with specific primary 
antibodies. Anti-occludin and anti-claudin-5 antibodies were purchased from Invitrogen, 
anti-actin antibody was from Sigma, and all secondary antibodies were from Santa Cruz 
Biotechnology.  
Brain microvessels smeared on the glass slides were incubated with anti-occludin 
and anti-claudin-5 antibodies for tight junction (TJ) immunoreactivity studies. 
 
Real-time RT-PCR 
Freshly isolated microvessels were resuspended in 200 μL of TRIZOL reagent 
(Invitrogen) and total RNA was extracted according to the manufacturer’s instructions. 
Then, 1 μg of RNA was reverse-transcribed using the Reverse Transcription System 
(Promega, Madison, WI). PCR amplification was performed using 3 μl of RT product, 
Taqman Universal PCR Master Mix (Applied Biosystems, Foster City, CA), and the pre-
developed primer pairs and Taqman probes (Applied Biosystems) in a total volume of 25 
μL. Expression of mRNA was calculated and analyzed by the comparative CT method as 
described earlier [221]. 
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Cultures of human brain microvascular endothelial cells and in vitro 
transendothelial migration 
Human brain microvascular endothelial cells (hCMEC/D3 cell line) were cultured 
as described previously [273]. For transendothelial migration, 1×105hCMEC/D3 cells 
were cultured on a Transwell filter until reaching confluency. Treatment factors were the 
same as in animal experiments; however, final concentration of PCB153 was 1.6 μM. 
Human monocytic THP-1 cells were stained with calcein acetoxymethyl (calcein AM) (5 
μM) for 15 min and added in the amount of 2.5×105 on top of hCMEC/D3 monolayers 
for 4 h at 37 °C. Fluorescence originating from the migrating THP-1 cells was measured 
in 200 μL aliquots collected in the lower compartment of the Transwell system at 485 nm 
excitation and 530 nm emission. 
 
Statistical analysis 
Statistical analysis was completed by using Sigma-Stat 2.03 (SPSS, Chicago, IL). 
One-way ANOVA, followed by Student- Newman-Keuls post hoc test or two-tailed 
Student’s t-test, was used to compare mean responses among the treatments. A statistical 
probability of p<0.05 was considered significant. 
 
4. Results 
Characterization of NPs and PCB153-NPs 
Nanoparticles are known to agglomerate in aqueous solutions. Both NPs and 
PCB153-NPs agglomerated in water PBS and EBM-2 generating aggregates with the 
average hydrodynamic diameter of ~250 nm for PCB153-NPs and ~350 nm for silica 
NPs alone (Table 3.1). Data reported here are based on Cumulants analysis. Z-average 
diameter is the mean diameter based on the intensity of scattered light, and the PDI 
describes the width of the particle size distribution, calculated as PDI=σ2/ZD2, where σ is 
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the standard deviation and ZD is the Z average mean size. An increase in the Z-average 
diameter is an indication of particle aggregation. 
As shown in Table 3.1, the size and PDI of NPs and PCB153-NPs vary in 
different media. Particles dispersed in PBS and EBM-2 displayed higher PDI value than 
in water, indicating less uniform dispersion. This may attribute to the ionic strength (IS), 
pH, or interaction of particles with serum proteins in cell culture medium. Therefore, 
during material preparation NPs were first dispersed in water and then diluted to final 
concentration in PBS.  
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Table 3.1. Hydrodynamic particle diameters of NPs in different media as determined by 
dynamic light scattering 
Particles  Z-Average Diameter (nm) PDI 
NPs    
Water 346.5 0.246 
PBS  346.3 0.610 
EBM-2  333.6 0.294 
PCB153-NPs    
Water 246.7 0.277 
PBS  265.8 0.442 
EBM-2  239.5 0.511 
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Disruption of TJ protein expression and the BBB integrity is enhanced in mice 
exposed to PCB153-NPs  
TJs are critical elements that regulate the integrity of the BBB. There was a 
tendency towards diminished levels of occludin after exposure to NPs or PCB153 alone; 
however, quantified results indicated that these changes did not reach statistical 
significance. Importantly, administration of PCB153-NPs resulted in a significant 
decrease in expression of occludin and claudin-5 in brain microvessels (Fig. 3.1 A and B, 
respectively) as determined by immunoblotting and immunoreactivity. 
Alterations of TJ molecular properties have been associated with disruption of 
BBB integrity [266]. Therefore, we evaluated the influence of PCB153 and/or NPs on the 
BBB function using an assay based on permeability of a fluorescent marker sodium 
fluorescein. As indicated in Fig. 3.2, exposure to PCB153-NPs significantly increased the 
BBB permeability. Such effects were not observed in animals treated with equimolar 
amount of PCB153 or NPs alone. 
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Figure 3.1. Treatment with PCB153-NPs disrupts expression of tight junction proteins 
and BBB integrity. Mice were exposed to PCB153-NPs by infusion into the internal 
carotid artery (ICA) at the dose of 5 ng PCB153/g body weight bound to 1.04×105 silica 
NPs. Control mice were infused with the same amounts of NPs, PCB153 dissolved in 
DMSO, or vehicle (PBS or 0.01 % DMSO). Brain microvessels were isolated 24 h post 
treatment and analyzed for occludin (A) and claudin-5 (B) expression by immunoblotting 
and immunofluorescence. Immunoreactivity of occluding and claudin-5 was stained in 
green and red, respectively; scale bar =20 μm. The blots in A and B are representative 
images from all experiments and the quantified results are depicted in the form of bar 
graphs. Arrows indicate disrupted continuity of tight junction proteins. Results are 
mean±SEM, n=4. *Significantly different as compared to control groups at *p<0.05 or 
***p<0.001. †Results in the PCB153-NP group are statistically different from those in 
the PCB153 group at † p<0.05 or ††† p<0.001. 
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Figure 3.2. Treatment with PCB153-NPs increases permeability of the BBB. Mice were 
injected with vehicle, PCB153 and/or NPs as in Figure 3.1. BBB permeability was 
evaluated using sodium fluorescein 24 h post treatment. Results are mean±SEM, n=4. 
***Significantly different as compared to other groups at p<0.001. 
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Exposure to PCB153-NPs potentiates inflammatory responses in brain capillaries 
Stimulation of proinflammatory responses is both the prominent feature of PCB-
induced toxicity in the brain [135] and an important element of stroke pathology. 
Therefore, we determined the effects of PCB153 and/or NPs on mRNA expression of 
proinflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) 
as well as adhesion molecules intercellular adhesion molecule-1 (ICAM-1) and vascular 
cell adhesion molecule-1 (VCAM-1) (Fig. 3.3). Exposure to NPs alone did not affect 
expression of these inflammatory mediators. Treatment with PCB153 alone significantly 
increased mRNA levels of TNF-α, IL-1β, and ICAM-1 but not VCAM-1. Importantly, 
exposure to PCB153-NPs resulted in significant elevation of mRNA of all 
proinflammatory mediators assessed in the present study as compared to both controls 
and PCB153 alone treated mice. 
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Figure 3.3. Exposure to PCB153-NPs potentiates inflammatory responses in brain 
capillaries. Mice were treated as in Figure 3.1, followed by brain microvessel isolation. 
mRNA levels of TNF-α (A), IL-1β (B), ICAM-1 (C), and VCAM-1 (D) were determined 
by real-time PCR. Results are mean±SEM, n=6. *Significantly different as compared to 
control groups at **p<0.01 or ***p<0.001. †Results in the PCB153-NPs group are 
statistically different from those in the PCB153 group at †p<0.05, ††p<0.01, or 
†††p<0.001. 
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Exposure to PCB153-NPs induces transcapillary migration of monocytes 
Because disruption of the barrier function of the brain endothelium is associated 
with migration of inflammatory cells into the brain, we evaluated these effects in mice 
exposed to PCB153 and/or NPs. Mice were injected through the ICA with mouse-derived 
monocytic J744.1 cells labeled with CFDA-SE. Brain slices were also stained for 
claudin-5 to visualize brain microvessels. Figure 3.4A indicates enhanced numbers of 
monocytic clusters in brain microvessels of mice treated with PCB153-NPs as compared 
to animals exposed to PCB153 alone. No attachment of labeled monocytes was detected 
in NP- or vehicle-treated animals. 
To further confirm these effects, in vitro studies were performed using human 
brain endothelial cells co-cultured with human monocytic THP-1 cells. As shown in Fig. 
3.4B, treatment with PCB153-NPs, but not with PCB153 or NPs, enhanced 
transmigration of THP-1 cells. 
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Figure 3.4. Treatment with PCB153-NPs enhances monocyte transmigration. (A) Mice 
were exposed to vehicle, PCB153, and/or NPs as in Figure 3.1, followed by injection 
with monocytic J774.1 cells labeled with CFDA-SE (green) into the internal carotid 
artery. In addition, brain sections were stained for claudin-5 (red) to visualize the vessels. 
Closed arrowheads indicate labeled J774.1 cells inside cerebral vessels, while open 
arrowheads indicate labeled J774.1 cells that appear to be present in the perivascular 
space. Scale bar =20 μm. (B) Confluent hCMEC/D3 cells cultured on Transwell inserts 
were treated with PCB153-NPs (PCB153, 1.6 μM; NPs, 2.08×105), PCB153 (1.6 μM), 
NPs (2.08×105), or vehicle for 24 h. THP-1 monocytic cells were labeled with calcein 
AM, added on the top of endothelial monolayers, and their transendothelial migration 
was assessed 4 h later. Data are mean±standard deviation (SD), n=6. *Significantly 
different as compared to control groups at p<0.05.  
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Exposure to PCB153-NPs potentiates brain injury in the experimental stroke model 
We next investigated how binding to NPs can affect toxicity of PCB153 in an 
experimental stroke model based on middle cerebral artery occlusion (MCAO). Mice 
were injected with vehicle, PCB153 and/or NPs, into cerebral circulation. Twenty four 
hours later, the animals were subjected to a 40 min MCAO, followed by a 24 h 
reperfusion. The infarct volume was evaluated using TTC staining. As indicated in Fig. 
3.5, exposure to PCB153-NPs significantly increased the infarct volume induced by 
ischemia/reperfusion as compared to all other treatment groups.  
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Figure 3.5. Exposure to PCB153-NPs increases the infarct volume in the experimental 
stroke model. Mice were treated as in Figure 3.1 and subjected to a 40 min MCAO, 
followed by a 24 h reperfusion, and staining with 2,3,5-triphenyltetrazolium chloride 
(TTC) to visualize viable tissue. Unstained area (arrows) corresponds to damaged brain 
tissue. Quantified results of negative TTC staining are depicted in the form of bar graphs. 
Results are mean±SEM, n=5–7. ***Significantly different as compared to other groups at 
p<0.001. 
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Long-term exposure to PCB153-NPs stimulates accumulation of PCB153 in adipose 
tissue and potentiates leukocyte attachment to the cerebral vessels 
In the final series of experiments, we changed the route of exposure and evaluated 
the effects of chronic (30 days) oral exposure to PCB153 and/or PCB153-NPs. Treatment 
with PCB153-NPs resulted in a significantly higher PCB153 accumulation in adipose 
tissue collected from abdominal cavity as compared to exposure to PCB153 alone (Fig. 
3.6A). Importantly, a chronic exposure to PCB153-NPs resulted in enhanced aggregation 
of leukocytes in brain vessels and perivascular space as visualized through cranial 
window (Fig. 3.6B). In contrast, chronic treatment with subtoxic levels PCB153 alone did 
not affect leukocyte aggregation in cerebral vessels. 
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Figure 3.6. Long-term exposure to PCB153-NPs potentiates PCB153 adipose 
accumulation and leukocyte attachment to cerebral vessels. (A) Mice were exposed orally 
to PCB153-NPs (5 ng PCB153/g body weight bound to 1.04×105 silica NPs), the 
equimolar dose of PCB153, or the appropriate vehicles for 30 days. PCB153 levels were 
assessed in adipose tissue. Results are mean±SEM, n=5–6. *Significantly different as 
compared to other groups at p<0.05. (B)Mice were exposed as in (A), followed by 
installation of the cranial window. Circulating leukocytes were fluorescently labeled by 
i.p. injection with rhodamine 6 G and the interactions of labeled leukocytes with the brain 
endothelium were detected via cranial window under fluorescent microscope. Arrows 
indicate leukocytes inside the cerebral vessels that appear to be attached to the brain 
endothelium. Scale bar=20 μm. 
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5. Discussion 
The transport modes of PCBs in the environment are multifarious, including 
binding of environmental PCBs to particulate matter (PM) [274]. In the current study, we 
hypothesized that such a binding may change toxicological properties of PCBs and 
influence risk assessment. To address this hypothesis, we evaluated cerebrovascular 
toxicity of PCB153 bound to silica NPs. The choice of PCB153 was based on the fact 
that it is one of the most prominent PCB congeners in the environment. Moreover, ortho-
substituted PCBs, such as PCB153, accumulate in the CNS [135, 258]. PM collected and 
analyzed in environmental samples is physically and chemically complex, making 
analyses of the biological effects of air pollution challenging. In contrast, engineered NPs 
are mono-dispersed and chemically pure. We used silica NPs as PCB153 carrier due to 
abundance of silica in the environment. Synthetic silica NPs, being chemically inert, are 
generally regarded as safe [275] and have been approved for use as food or animal-feed 
ingredient as well as in diagnostic and biomedical research [276]. Importantly, silica NPs 
employed in the present study were in the similar size range as particles present in the 
environment.  
Once deposited, the fate of NPs depends on their chemical structure and targeted 
organs. NPs can reach the CNS through the sensory nerves embedded in the airway 
epithelia [149], and/or directly through the BBB [150, 151]. While specific NPs can be 
biodegraded and/or cleared from tissues via the gastrointestinal tract, lymphatic system, 
and blood circulation, we demonstrated that NPs, such as nano-alumina can still be 
detected in the brain several days after the initial exposure, causing long lasting effects 
[277].  
Results of the present study indicate that animals exposed to PCB153 bound to 
silica NPs exhibit a dramatic increase in BBB permeability and decrease of TJ protein 
expression, effects that are not observed in animals exposed to an equal amount of 
PCB153 alone. Although specific mechanisms of PCB153-NP-induced disruption of 
BBB integrity are not known, redox-responsive reactions might be involved in this event. 
The brain is an organ that is highly vulnerable to oxidative stress due to its high content 
of iron and lipids, high oxygen consumption, and relatively low capacity of antioxidant 
73 
 
defenses [144]. Such properties make the brain susceptible to PCB-induced injury, as 
PCBs are recognized as potent inducers of oxidative stress [141, 278]. In fact, a recent 
study published by our group indicated that PCB153 can induce cellular oxidation acting 
through the NADPH oxidase complex [143]. Moreover, exposure to particulate matter 
can also induce production of reactive oxygen species (ROS) in rat brain capillaries, 
resulting in alterations of expression of TJ proteins [178]. An increase in oxidative stress 
may provide a common trigger for downstream events that regulate BBB integrity. For 
example, oxidative stress-induced alterations of TJ proteins may act through Ras and Rho 
redox responsive elements [279]. Upon activation, Rho phosphorylates downstream 
molecules such as Rho kinase (ROCK), which then results in increased myosin light 
chain (MLC) phosphorylation via inhibition of MLC phosphatases [280]. Oxidative stress 
can also lead to the elevation of chemokine receptors at the brain endothelium, further 
contributing to MLC phosphorylation through the activation of myosin light chain kinase 
(MLCK) [281]. MLCK can modulate actin structure and phosphorylate TJ proteins, 
which results in the cytoskeletal reorganization. Under conditions of oxidative stress, 
activated protein tyrosine kinases (PTKs) may also trigger activation of matrix 
metalloproteinases (MMPs), which can degrade the endothelium basement membrane, 
leading to the disruption of the BBB [34]. 
Recent reports from our laboratory implicate the brain endothelium as an 
important target of vascular toxicity of PCBs. Indeed, exposure to specific PCB 
congeners, including PCB153, stimulates induction of adhesion molecules and induces 
leukocyte adhesion [143, 282]. These effects are important because inflammatory 
responses involving cerebral vessels contribute to the development of neuroinflammation, 
constitute the risk of onset of stroke, and potentiate tissue damage in brain 
ischemia/reperfusion [71]. Upregulation of ICAM-1 and VCAM-1 expression by brain 
endothelial cells has also been associated with multiple sclerosis, encephalitis, and other 
inflammatory conditions in the brain [283]. Therefore, it is of significant clinical 
relevance that exposure to PCB153-NPs results in more pronounced expression of 
proinflammatory mediators as compared to treatment with PCB153 alone. 
Overexpression of inflammatory cytokines, such as TNF-α and IL-1β, can further 
stimulate production of proinflammatory mediators, impair BBB functions, and recruit 
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inflammatory cells. Moreover, inflammatory cytokines can induce expression of adhesion 
molecules on endothelial cells, facilitating the adherence of leukocytes to the brain 
endothelium. A functional BBB is critical in maintaining the immune-privileged status of 
the brain. Thus, a strategy targeting inhibition of proinflammatory mediators may help to 
protect against PCB- or other environment pollutantinduced BBB dysfunction. 
Increased expression of adhesion molecules results in enhanced adhesive 
properties of endothelial cells and stimulation of adhesion of leukocytes to the brain 
endothelium [234, 284]. Therefore, we investigated the influence of PCB153 and/or NPs 
on leukocyte adhesion using both in vivo and in vitro models. Visualization of leukocyte-
endothelium interaction was accomplished in vivo by detection of labeled leukocytes by 
fluorescent microscopy via a cranial window. While this method is suitable to study the 
interactions of leukocytes with brain microvessels, in vitro modeling of transendothelial 
migration of monocyte allows for quantitative comparison among different treatments. 
Consistent with the effects on expression of proinflammatory mediators, both 
acute and chronic administration of PCB153-NPs significantly upregulate monocyte 
attachment to the brain endothelium, with PCB153 having only a moderate effect. These 
results indicate that brain microvessels can recognize and respond to PCB153-NPs by 
producing proinflammatory molecules. This response may serve as a proinflammatory 
sensor and ultimately distribute ROS and cytokines, further contributing to the CNS 
pathology. 
Enhanced cerebrovascular toxicity of PCB153-NPs, as compared to PCB153 
alone, may result from more effective bioaccumulation of these toxicants. The properties 
of NPs as effective carriers across the BBB are well described and have been used for 
drug delivery into the brain [285]. Another possibility is lower excretion rate of PCB153-
NPs due to the longer retention of NPs [286]. Indeed, we observed a higher PCB153 
body burden in animals chronically exposed to PCB153-NPs than in PCB153 alone. 
These measurements were performed in adipose tissue to reflect lifetime PCB 
bioaccumulation [287]. Because chronic exposure to PCB153 and/or NPs was 
administered, effects of PCB153 and NPs on intestinal epithelium might also contribute 
to increased PCB153 absorption into the blood stream. In fact, we recently demonstrated 
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that oral exposure to PCBs can disrupt TJ proteins in small intestine and increase 
intestinal permeability [278]. 
Epidemiologic studies and laboratory evidence demonstrate that exposure to 
PCBs may enhance the risk for stroke and other vascular disorders [14, 130]. Therefore, 
one aim of the present study was to investigate the effects of PCB153 and/or NPs on the 
development and outcome of stroke. We detected a larger stroke volume in mice exposed 
to PCB153-NPs, as compared to other treatment groups, which was consistent with the 
effects of these toxicants on TJ protein expression and proinflammatory responses. 
Indeed, endothelial activation, proinflammatory and prothrombotic interactions between 
the vessel wall and circulating blood constituents are known risk factors triggering the 
onset of stroke [288]. 
In summary, we demonstrate for the first time that binding of PCB153 to silica 
NPs can increase cerebrovascular toxicity of these toxicants by enhancing 
proinflammatory responses and disruption of the BBB integrity. These effects appear to 
predispose mice to stroke and potentiate brain injury associated with 
ischemia/reperfusion. Our results also emphasize the importance of risk assessment for 
NPs by demonstrating that even chemically inert silica NPs can markedly influence 
toxicity of other environmental chemicals, such as PCBs. 
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Chapter four: TLR4 signaling is involved in brain vascular toxicity of PCB153 
bound to nanoparticles 
 
1. Synopsis 
PCBs bind to environmental particles; however, potential toxicity exhibited by 
such complexes is not well understood. The aim of the present study was to study the 
hypothesis that assembling onto nanoparticles can influence the PCB153-induced brain 
endothelial toxicity via interaction with the toll-like receptor 4 (TLR4). To address this 
hypothesis, TLR4-deficient and wild type control mice (males, 10 week old) were 
exposed to PCB153 (5 ng/g body weight) bound to chemically inert silica nanoparticles 
(PCB153-NPs), PCB153 alone, silica nanoparticles (NPs; diameter, 20 nm), or vehicle. 
Selected animals were also subjected to 40 min ischemia, followed by a 24 h reperfusion. 
As compared to exposure to PCB153 alone, treatment with PCB153-NP potentiated the 
brain infarct volume in control mice. Importantly, this effect was attenuated in TLR4-
deficient mice. Similarly, PCB153-NP-induced proinflammatory responses and 
disruption of tight junction integrity were less pronounced in TLR4-deficient mice as 
compared to control animals. Additional in vitro experiments revealed that TLR4 
mediates toxicity of PCB153-NP via recruitment of tumor necrosis factor-associated 
factor 6 (TRAF6). The results of current study indicate that binding of PCBs to 
seemingly inert nanoparticles increase their cerebrovascular toxicity and suggest that 
targeting the TLR4/TRAF6 signaling may protect against these effects.   
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2. Introduction 
Environmental exposure to polychlorinated biphenyls (PCBs) is an ongoing 
environmental problem. Because of their chemical stability, slow degradation rate, and 
high tendency to bioaccumulate in the food chain, PCBs are among the most persistent 
and widespread organic pollutants [253]. The fate and transport of PCBs are associated 
with the specific structure of individual PCB congeners. PCBs are readily adsorbed onto 
particles, such as atmospheric particulates, soil, and sediments. Recent publications have 
reported PCBs bound to particles ranging from 0.95 µm to 1.5 µm in ambient air [260-
262]. 
Exposure to PCBs has been linked to various adverse health effects in humans. 
Recent reports from a PCB contaminated site located in Anniston, AL indicated that 
serum PCB levels are highly associated with increased prevalence of diabetes [256] and 
hypertension [132]. These diseases are considered to be risk factors for stroke. In fact, an 
increase in the incidence of stroke was observed in people exposed to PCBs [289, 290] 
and living in proximity to PCB hazardous wastes [14]. These observations are important 
because stroke is one of the leading causes of death worldwide.  
 A functional blood-brain barrier (BBB) is the key element for the homeostasis of 
the central nervous system (CNS). The BBB consists of highly specialized brain 
endothelial cells that are characterized by the unique phenotype of intercellular tight 
junctions (TJs) and numerous polarized transport systems [51]. Disruption of TJ proteins 
is often observed during acute and chronic diseases of the CNS, including stroke [291]. 
Our research group reported that oral administration of selective PCB congeners resulted 
in accumulation of PCBs in brain tissue and increased permeability of the BBB [135, 144, 
282]. Highly chlorinated ortho-PCBs preferentially accumulate in brain tissue and are 
associated with several CNS diseases, such as Parkinson’s disease [292] or 
developmental alterations [293]. The most representative ortho-PCB congener is 
2,2′,4,4′,5,5′-hexachlorobiphenyl (PCB153), which is commonly detected in human [259, 
294] and in environmental samples, including atmospheric particulates [295, 296]. We 
hypothesize that binding of PCB153 to nanoparticles (NPs) can influence their toxic 
properties. However, the mechanisms by which PCB153-NP complexes are sensed and 
transduced via cellular signaling are largely unknown.  
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Biological systems universally respond to various stimuli of environmental 
signals by using evolutionarily conserved mechanisms [297, 298]. One such example is 
toll-like receptors (TLRs), which recognize and respond to an expansive variety of 
environmental and pathogen associated molecular stimuli [299, 300]. TLRs are widely 
expressed in various cell types in the brain, including microglia, astrocytes, neurons, and 
endothelial cells [301, 302]. Recent evidence indicates that TLR4, the first characterized 
of mammalian TLRs, may play a vital role in ischemia/reperfusion injury [180, 303].  
In the present study, we hypothesize that exposure to PCB153 assembled onto 
nanoparticles contributes to the development of stroke by disruption of the integrity of 
the cerebral endothelium and induction of proinflammatory responses through 
stimulation of TLR4 signaling.  The results of the present study support this notion and 
indicate that targeting of the TLR4/tumor necrosis factor-associated factor 6 (TRAF6) 
signaling can protect against cerebrovascular toxicity of PCB153-NP complexes.   
 
3. Materials and Methods 
Materials 
2,2′,4,4′,5,5′-hexachlorobiphenyl (PCB153) congener was purchased from 
AccuStandard (New Haven, CT) and silica NPs from NanoAmor (Houston, TX). 
Characterization of NPs and construction of silica NPs coated with PCB153 were 
described in our previous study [293]. Briefly, silica NPs (80 mg) and PCB153 (10 mg) 
were dispersed in acetone and sonicated to prevent aggregation. The highly hydrophobic 
surface character of PCB153 and silica NPs allows them to interact with each other based 
on electrostatic attraction. After evaporation of acetone, the particles were resuspended in 
phosphate buffered saline (PBS) or cell culture medium, sonicated, and centrifuged at 
12,000 rpm for 5 min.  The supernatant containing PCB153-NPs was then collected to 
analyze PCB153 levels by gas chromatography/mass spectrometry (GC/MS).  The 
hydrodynamic size distribution and the amounts of PCB153-NPs were monitored by 
dynamic light scattering (DLS) and atomic force microscope (AFM), respectively.  
Control NPs were prepared using the same procedure, without adding PCB153. All 
treatment factors were tested for possible endotoxin contamination using the LAL 
chromogenic endotoxin quantitation kit (Thermo Scientific Pierce, Rockford, IL). The 
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levels of endotoxin in all preparations were below the detection limit, indicating no 
contamination.  
 
Experimental groups and surgical procedures 
All experimental procedures and protocols were approved by the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. C3H/HeJ mice 
contain a point mutation in the TLR4 gene and are TLR4-deficient, whereas C3H/HeouJ 
mice express normal TLR4 activity and were used as controls. Mice (males, 10-12 weeks 
old; Jackson Laboratories) were infused with a) PCB153 bound to nanoparticles 
(PCB153-NPs), b) PCB153 dissolved in 0.01% DMSO (PCB153), c) nanoparticles (NPs) 
alone, or d) vehicle (PBS). PCB153 was administered in the amount of 5 ng/g body 
weight. All infusions were performed through the internal carotid artery (ICA) using a 
surgical technique standarzied by our research group [270] for selective drug delivery 
into the brain vasculature. 
Transient focal cerebral ischemia was induced by a 40 min occlusion of the 
middle cerebral artery (MCA), following a 24 h reperfusion as described previously [304]. 
In anesthetized mice, a 6-0 surgical nylon suture coated with silicon (Doccol, Redlands, 
CA) was advanced through the left common carotid artery and up to the ICA to block the 
origin of the MCA. After occlusion for 40 min, reperfusion was initiated by removing the 
suture to restore the blood flow.  
 
Assessment of the infarct volume 
The mouse brain was removed and sectioned into 7 coronal slices with 1 mm 
thickness from the frontal pole to the occipital pole using a coronal acrylic matrice 
(Braintree Sci., Braintree, MA). The brain slices were then stained with 2% 2,3,5-
triphenyltetrazolium chloride (TTC) at 37 °C for 20 min. The viable brain tissue was 
stained in red, whereas the infarcted area appeared unstained. The infarct size and volume 
were calculated using ImageJ software as previously described [271]. 
 
Brain microvessel isolation  
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Isolation of brain microvessels was performed as described previously [144]. 
After removing meninges and choroids plexus, brain tissue was homogenized in ice-cold 
buffer containing 103 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM 
MgSO4, 15 mM HEPES, 25 mM NaHCO3, 10 mM glucose, 1 mM Na pyruvate, 10 g/L 
dextran and protease inhibitor cocktail tablets (Roche Diagnostics, Indianapolis, IN). The 
homogenates were mixed with 26% dextran and centrifuged at 5,800 × g at 4 °C for 20 
min. The collected pellets were resuspended in ice-cold buffer and filtered through a 70 
µm cell strainer (BD Biosciences, San Jose, CA). Filtered samples were re-pelleted by 
centrifugation, followed by either resuspension in 150 µL of 6 M urea lysis buffer for 
Western blot analyses, or resuspension in 200 µl of TRIZOL (Invitrogen, Carlsbad, CA) 
for total RNA extraction.  
 
Cell cultures, treatment factors, and gene silencing 
 Human brain endothelial cells (hCMEC/D3 cell line) were cultured as previously 
described [143]. Confluent cultures were exposed to PCB153-NPs, NPs, PCB153 alone, 
or vehicle for 24 h. In cell culture experiments, PCB153 was used in subtoxic 
concentration of 1.6 μM, which is lower than the levels reported in humans acutely 
exposed to PCBs [305, 306].  In selected experiments, cultured cells were treated with 10 
μM CLI095, a pharmacological inhibitor of TLR4, which blocks the signaling mediated 
by the intracellular domain of TLR4.  
 Cultured cells at 70-80% confluency were transfected with 60 nM of control or 
TRAF6 specific siRNA (Applied Biosystems, Carlsbad, CA) using GeneSilencer 
(Genlantis, San Diego, CA).  The cells were incubated with transfection mixtures for 24 h 
and allowed to recover in complete medium for 48 h before exposure to PCB153 and/or 
NPs.  
 
Immunoblotting and immunoprecipitation 
 Immunoblotting was performed with either whole cell lysates (30 µg protein per 
sample) prepared in RIPA lysis buffer (50 mM Tris–HCl pH 7.4, 1% NP-40, 0.25% 
sodium deoxycholate, 150 mM NaCl, and 1 mM EDTA) or lysed mouse brain 
microvessels (50 µg protein per sample). Protein samples were separated on SDS-
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polyacrylamide gel, blotted onto polyvinyl difluoride membranes (Bio-Rad Laboratories, 
Hercules, CA), and incubated with the respective antibodies. Anti-occludin and anti-
claudin-5 antibodies were from Invitrogen, anti-TLR4 antibody from Santa Cruz 
Biotechnology (Santa Cruz, CA), anti-actin antibody from Sigma, and all secondary 
antibodies from Cell Signaling Technology (Danvers, MA). For visualization of detected 
proteins, immunoblots were analyzed using an ECL Western blot detection kit (GE 
Healthcare Life Sciences, Piscataway, NJ) and proteins of interest were semi-quantitated 
with ImageJ software.  
 Immunoprecipitation of TRAF6 was performed using 800 µg of protein extracted 
from whole cell lysate. Samples were incubated with 1 μg of anti-TRAF6 antibody (Cell 
Signaling Technology) overnight at 4 °C. Next day, 30 μL of Protein A/G Plus Agarose 
(Thermo Scientific Pierce, Rockford, IL) was added to each sample and 
immunoprecipitation was performed for 2 h at 4 °C. Bound proteins were eluted by 
boiling in SDS sample buffer for 5 min and analyzed on SDS-polyacrylamide gel.  
 
Real-time RT-PCR 
Total RNA was extracted from freshly isolated microvessels using TRIZOL 
reagent (Invitrogen) according to the manufacturer’s instructions with an additional 
chloroform extraction, phase separation, and an extra wash in 70% ethanol. Then, 1 µg of 
RNA was reverse-transcribed using the Reverse Transcription System (Promega, 
Madison, WI) and 3 µL of final RT product was used for PCR amplification. Taqman 
Universal PCR Master Mix, pre-developed primer pairs and probes were purchased from 
Applied Biosystesms (Foster City, CA). The following thermocycling conditions were 
employed: 95 °C for 10 min, followed by 95 °C for 15 sec, and 60 °C for 60 sec (for up 
to 40 cycles). Expression of mRNA was calculated and analyzed by the comparative CT 
method as described [221].  
 
ELISA 
The levels of cytokines and chemokines in cell culture media were determined 
using Multi-Analyte ELISArray kit (Qiagen, Valencia, CA). Briefly, 50 μL aliquots of 
culture media were added into individual wells of the ELISArray kit and incubated at 
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room temperature for 2 h. After the plate was washed three times with washing buffer, 50 
μL of biotin-conjugated anti-IL-6, anti- CXCL-8, anti-CCL-2, and anti-CCL-5 antibodies 
were added into indicated wells and incubated at temperature for 1 h. Then, the plate was 
washed three times and avidin-conjugated horseradish peroxidase was added to each well 
for 30 min incubation at room temperature, followed by four washings with the washing 
buffer. After 15 min incubation with development solution, stop solution was added to 
each well and the absorbance was measured at 450 nm using SpectraMax 190 absorbance 
microplate reader (Molecular Devices, Sunnyvale, CA). The standard curve was 
generated using antigen standard of each target protein at the concentrations between 0 to 
200 pg/mL.  
 
Statistical analysis 
Statistical analysis was completed using SigmaPlot 12.0 (Systat Software, San 
Jose, CA). One-way or Two-way ANOVA followed by Holm-Sidak post hoc test was 
used to compare mean responses among the treatments. A statistical probability of p<0.05 
was considered significant. 
 
4. Results 
TLR4 deficiency diminishes PCB153-NP-induced enhancement of infarct volume 
and disruption of the BBB integrity 
To test the hypothesis that PCB153-NPs potentiate the ischemic injury through 
activation of TLR4, mice with a point mutation in the TLR4 gene (C3H/HeJ) and mice 
expressing normal TLR4 activity (C3H/HeouJ) were employed.  As indicated in Figure 
4.1, exposure to PCB153-NPs significantly increased the infarct volume in the control 
mice as compared to treatment with vehicle (PBS), NPs, or PCB153 alone. However, 
TLR4-deficient mice infused with PCB153-NPs showed significantly smaller infarct 
volume as compared to control mice.  
Disruption of TJs is a typical event during cerebral ischemia. Therefore, we 
evaluated the effects of PCB153 and/or NPs on expression of transmembrane TJ proteins, 
such as occludin and claudin-5 as well as TJ-associated protein ZO-1 both in animals and 
cell cultures of brain endothelial cells. Exposure to PCB153-NPs but not to PCB153 or 
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NPs alone resulted in a decrease in claudin-5 and ZO-1 levels in mice with normal TLR4 
expression, whereas deficiency of TLR4 diminished the effect (Figure 4.2A). Consistent 
with these results, levels of occludin and claudin-5 were also markedly reduced following 
exposure to PCB153-NPs in brain endothelial cells. Importantly, inhibition of TLR4 
activity with CLI095 attenuated these effects (Figure 4.2B), further indicating that TLR4 
pathways is involved in PCB153-NP-induced alteration of TJ expression. 
Overexpression of proinflammatory cytokines, chemokines, and adhesion 
molecules in the brain is hallmark of neuroinflammation. Therefore, we evaluated the 
expression levels of proinflammatory cytokines (IL-6 and CXCL-8 [IL-8]), chemokines 
(CCL-2 and CCL-5 [RANTES]) and adhesion molecule ICAM-1 following exposure to 
PCB153 and/or NPs in brain microvessels and cultured brain endothelial cells. As shown 
in Figure 4.3A, mRNA levels of IL-6, CCL-2, CCL-5, and ICAM-1 were significantly 
elevated in brain capillaries of wild type mice exposed to PCB153-NPs but not to 
PCB153 or NPs alone.  Importantly, deficiency of TLR4 effectively protected against 
these effects.  Inhibition of TLR4 signaling by CLI095 also attenuated PCB153-NP-
induced overproduction of IL-6, CXCL-8, CCL-2 and CCL-5 protein levels in cultured 
human brain endothelial cells (Figure 4.3B). 
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Figure 4.1. PCB153-NP-induced enhancement of infarct volume following 
ischemia/reperfusion is reduced in TLR4-deficient mice. Mice were exposed to PCB153-
NPs (5 ng PCB153/g body weight bound to 1.04 x 105 silica NPs) by infusion into the 
internal carotid artery (ICA). Control mice were infused with the same amounts of NPs, 
PCB153 or vehicle (PBS). After 24 h, all animals were subjected to a 40 min occlusion of 
the middle cerebral artery (MCA), followed by a 24 h reperfusion. The infarct area was 
detected by 2,3,5-triphenyltetrazolium chloride (TTC) staining and the image illustrates 
the representative results. The loss of tissue viability is reflected by unstained (white) 
areas. Quantified results are depicted in a bar graph. Results are means ± SEM, n=5. 
Significantly different as compared to vehicle treatment in mice with normal TLR4 
expression at ***p<0.001. Results in the TLR4-deficient mice treated with PCB153-NPs 
are statistically different from those in control animals exposed to PCB153-NPs at 
###p<0.001. 
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Figure 4.2. TLR4 is involved in PCB153-NP-induced TJ protein disruption. (A) Mice 
were infsed with PCB153-NPs or control treatments as in Figure 4.1. Expression of ZO-1 
and claudin-5 was analyzed in brain microvessels isolated from TLR4-deficient or 
control mice by immunoblotting. Results are means ± SEM, n=5. Significantly different 
as compared to control treatments in normal mice at *p<0.05. Results in the TLR4-
deficient mice treated with PCB153-NPs are statistically different from those in control 
animals exposed to PCB153-NPs at #p<0.05. (B) Confluent brain endothelial cell cultures 
were treated with PCB153-NPs (PCB153, 1.6 µM; NPs, 2.08 x 105), or the same amounts 
of PCB153, NPs, or vehicle for 24 h. Selective cultures were pretreated with TLR4 
inhibitor CLI095 (10 μM) or vehicle (DMSO, 0.01%) for 1 h, followed by co-exposure to 
PCB153 and/or NPs for 24 h. TLR4 inhibitor was retained in media throughout PCB153 
and/or NPs treatment.  Occludin and claudin-5 levels were measured by immunoblotting. 
Results are means ± SD, n=5. Significantly different as compared to vehicle at *p<0.05 
or ***p<0.001. Results in cultures pretreated with CLI095 are statistically different from 
those in the corresponding cultures without added CLI095 at #p<0.05 or ###p<0.001. 
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Figure 4.3. Exposure to PCB153-NPs promotes inflammatory responses via TLR4. (A) 
Mice were treated as in Figure 4.1. mRNA levels of IL-6, ICAM-1, CCL-2 (MCP-1) and 
CCL-5 (RANTES) were determined in isolated brain microvessels by real-time PCR. 
Results are means ± SEM, n=5. Significantly different as compared to vehicle treatments 
in normal mice at *p<0.05, or ***p<0.001. Results in the TLR4-deficient mice treated 
with PCB153-NPs are statistically different from those in control animals exposed to 
PCB153-NPs at #p<0.05 or ###p<0.001. (B) Confluent brain endothelial cells were 
treated as in Figure 4.2B for 24 h.  Protein levels of IL-6, CXCL-8 (IL-8), CCL-2 and 
CCL-5 were determined by ELISA in cell culture supernatants. Significantly different as 
compared to vehicle at ***p<0.001. Results in cultures pretreated with CLI095 are 
statistically different from those in the corresponding cultures without added CLI095 at 
##p<0.01 or ###p<0.001.   
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Exposure to PCB153-NPs induces TRAF6 interaction with TLR4 
Upon activation, TLRs recruit adaptor molecules, such as MyD88, which then 
activate a series of downstream signaling molecules, including TRAF6 [300]. To 
investigate these events, brain endothelial cells were treated with PCB153-NPs for up to 
4 h. Cell lysates were then immunoprecipitated with anti-TRAF6 antibody and probed for 
TLR4.  Figure 4.4A indicates that PCB153-NPs induced a rapid (10 min) but transient 
recruitment of TRAF6 to TLR4.  Treatment with PCB153 alone for 10 min also resulted 
in binding of TRAF6 to TLR4; however, this effect was less prominent as compared to 
PCB153-NPs (Figure 4.4B). 
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Figure 4.4. Exposure to PCB153-NPs induces TLR4 interaction with TRAF6. (A) 
Confluent brain endothelial cells were treated with PCB153-NPs for the indicated time. 
Cellular extracts were immunoprecipitated using anti-TRAF6 antibody, followed by 
immunoblotting with anti-TLR4 antibody. (B) Confluent brain endothelial cells were 
exposed to PCB153 and/or NPs for 10 min, followed by determination of TLR4 
interaction with TRAF6 as in Figure 4.4A.  The blot illustrates the representative data of 
four independent experiments and the bar graph shows quantified results.  Results are the 
mean ± SD, n=4. Significantly different as compared to vehicle treatments in normal 
mice at *p<0.05. 
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TRAF6 mediates PCB153-NP-induced alterations in TJ protein expression and 
proinflammatory responses 
To investigate the involvement of TRAF6 in PCB153-NP-mediated TJ disruption, 
expression of TRAF6 in brain endothelial cells was silenced with TRAF6 siRNA (Figure 
4.5A), followed by exposure to PCB153 and/or NPs for 24 h. The results indicated that 
silencing of TRAF6 markedly protected against PCB153-NP-mediated reduction in 
occludin (Figure 4.5B) and claudin-5 (Figure 4.5C) protein levels. 
In the last series of experiments, we investigated the role of TRAF6 in PCB153-
NP-stimulated production of inflammatory mediators. Consistent with the results in 
Figure 3B, exposure to PCB153-NPs significantly increased the production of IL-6, 
CXCL-8, CCL-2 and CCL-5 in brain endothelial cells transfected with scrambled 
(control) siRNA. Importantly, silencing of TRAF6 effectively reduced the production of 
these inflammatory mediators in response to PCB153-NPs (Figure 4.6). 
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Figure 4.5. TRAF6 mediates PCB153-NP-induced a decrease in TJ protein expression. 
(A) Immunoblotting illustrating the efficiency of TRAF6 silencing. (B and C). Human 
brain endothelial cells were transfected with TRAF6 siRNA, followed by treatment with 
PCB153 and/or NPs as in Figure 4.2B for 24 h. Expression of occludin (B) and claudin-5 
(C) was assessed by immunoblotting. The blot illustrates the representative data of four 
independent experiments and the bar graph shows quantified results. Results are means ± 
SEM. Significantly different as compared to vehicle at *p<0.05 or **p<0.01. Results in 
cultures with silenced TRAF6 are statistically different from those in the corresponding 
cultures transfected with control (scrambled) siRNA at #p<0.05 or ##p<0.01.   
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Figure 4.6. TRAF6 mediates PCB153-NP-induced production of inflammatory mediators. 
Human brain endothelial cells were treated as in Figures 4.5B and C, followed by the 
assessment of IL-6, CXCL-8, CCL-2 and CCL-5 in culture medium by ELISA. Results 
are means ± SD, n=4. Significantly different as compared to vehicle at ***p<0.001. 
Results in cultures with silenced TRAF6 are statistically different from those in the 
corresponding cultures transfected with control (scrambled) siRNA at ###p<0.001. 
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5. Discussion 
While the cellular effects of dioxin-like PCBs are linked to activation of the aryl 
hydrocarbon receptor (AhR), signal transduction mechanisms induced by ortho-PCBs are 
complex and include more diverse number of receptors and signaling pathways. Non-
coplanar PCBs, such as PCB153 used in the present study, possess at least two ortho 
chlorines on the biphenyl ring, which generate steric forces that rotate the ring structure 
away from a single plane. Such a structure precludes interactions with the AhR; however, 
ortho-PCB congeners can act as ligands for the constitutive andorstane receptor (CAR) 
and/or the pregnane-X receptor (PXR), and activate genes targeted by these receptors 
[307]. In addition to the nuclear receptors, ryanodine receptors (RyRs) have also been 
identified as candidates to mediate ortho-PCB-induced perturbations in cellular Ca2+ 
signaling, which plays a pivotal role in metabolism, proliferation, gene transcription, and 
protein translation in almost all cell types [308]. For example, PCB95 and PCB153 at 
concentrations lower than 1 μM were shown to significantly enhance activity of RyR1 
and RyR2 [309]. Furthermore, ortho-PCBs can activate several signaling cascades 
including Janus kinase (JAK), epidermal growth factor receptor (EGFR), Src kinase, and 
mitogen-activated protein kinase (MAPK) [142, 310, 311]. We demonstrated that 
PCB153 upregulates expression of ICAM-1 and VCAM-1 through the Src/JAK/EGFR 
redox signaling, which is triggered by the NADPH oxidase-mediated increase of 
superoxide generation [143].  
In the current study, we present evidence that TLR4 is yet another cellular 
receptor that is involved in ortho-PCB-mediated vascular toxicity [312]. While it is 
generally accepted that TLRs are sensors of a variety of biological molecules, like 
polysaccharides, proteins and nucleic acids [313], our observations that a non-biological 
material, such as PCB153-NPs, can act via the TLR4 signaling pathway are novel.  By 
inhibition of TLR4 activity via pharmacological inhibitors and by using TLR4 deficient 
mice, we demonstrated that proinflammatory effects of PCB153-NPs are sensed via 
TLR4 in both brain microvessels and brain endothelial cells. These proinflammatory 
mediators are actively involved in the development of cerebrovascular and neurovascular 
alterations. ICAM-1 is an adhesion molecule which stimulates firm adhesion of 
leukocytes to the vascular endothelium and plays a critical role in the pathology of 
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numerous proinflammatory vascular diseases, including atherosclerosis [314]. CXCL-8 is 
one of the CXC chemokine members that has potent chemotactic activity for neutrophils 
[315]. It has also been shown that CXCL-8 can induce generation of superoxide and 
hydrogen peroxide [316] as well as increase expression of adhesion molecules [317, 318]. 
CC chemokines, such as CCL-2 and CCL-5, are implicated in the activation of 
monocytes, macrophages and lymphocytes [319]. Additionally, CCL-2 stimulates 
monocytes to produce tissue factor and proinflammatory cytokines, including IL-6 [36]. 
An elevated IL-6 level is associated with an increased infarct volume and severity of 
stroke outcome [320, 321].  
Activation of TLR4 results in interaction of its intracellular TIR domain with 
MyD88, whose amino-terminal death domain (DD) associates with the serine kinase IL-1 
receptor-associated kinase (IRAK).  These events subsequently recruit TRAF6 [299], 
followed by nuclear translocation of proinflammatory transcription factors NF-κB and 
AP-1. In agreement with this general pathway, we observed that treatment of brain 
endothelial cells with PCB153-NPs resulted in binding of TRAF6 to TLR4. While these 
interactions were transient, their importance was evident as silencing of TRAF6 
significantly attenuated PCB153-NP-induced overproduction of inflammatory mediators.   
Although the involvement of TLR4 in modulating BBB disruption has been 
reported [322], the precise mechanisms involved are not fully understood. Therefore, our 
observation that TLR4 signaling modulates PCB153-NP-induced disruption of TJ protein 
expression is another novel finding in the current study. We propose that TLR4 mediated 
an increase in inflammatory mediators, which may be responsible, at least in part, for 
these effects.  Indeed, CCL-2 has been reported to induce occludin phosphorylation on 
both serine/threonine residues, resulting in increased BBB permeability. Furthermore, 
CCL-2 targets ZO-1 and claudin-5 phosphorylation through a signaling pathway 
involving Rho and protein kinase C (PKC) [53, 323]. It was also reported that 
TLR4/TRAF6 signaling is involved in nanomaterial-induced autophagy formation [324]. 
While autophagy is a highly conserved pathway of intracellular protein degradation [325, 
326], our laboratory provided evidence that stimulation of autophagy in brain endothelial 
cells is associated with decreased expression of the TJ proteins [277].  
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Dysregulation of TLR4 signaling appears to be involved in several disorders, 
including cerebral ischemia and stroke [180, 202]. Consistent with these reports, we 
observed that the infarct volume in TLR4-deficient mice treated with PCB153-NPs was 
significantly decreased as compared to mice with normal expression TLR4. While a 
variety of factors can contribute to the development of stroke, the pathology of 
ischemia/reperfusion has a very strong inflammatory component [327]. Therefore, 
inflammatory responses induced by PCB153-NPs in cerebral vessels are likely to be 
responsible for the development of enhanced brain infarct.  BBB breakdown, due to 
disruption of TJs and infiltration with inflammatory cells, may be another contributing 
factor to the progress of the brain injury following ischemia/reperfusion and exposure to 
PCB153-NPs.   
In summary, our study demonstrates that exposure to PCB153 bound onto silica 
nanoparticles triggers TLR4/TRAF6-regulated inflammatory responses and alterations of 
TJ protein expression, which then contribute to enhanced brain injury following 
ischemia/reperfusion (Figure 4.7). These results indicate an important role for TLR4 
signaling in PCB-mediated cerebrovascular toxicity, suggesting that this signaling 
pathway may be a potential target for therapeutic intervention in cerebrovascular 
disorders.   
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Figure 4.1. Schematic diagram of PCB153-NP-induced cerebrovascular toxicity via 
stimulation of the TLR4. Binding of PCB153 to silica nanoparticles activates the TLR4 
and triggers its interaction with downstream molecule TRAF6. These events 
subsequently initiate overexpression of proinflammatory mediated and decreased 
expression of TJ proteins in brain endothelial cells. Disrupted BBB and enhanced 
neuroinflammatory responses contribute to enhanced brain injury in experimental stroke 
model.   
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Chapter five: Overall discussion 
1. Summary 
The work presented in this dissertation provides the evidence that disruption of 
the BBB contributes to the brain ischemic injury. This phenomenon was evaluated in 
models of telomerase deficiency animals and mice exposed to environmental pollutants, 
such as PCBs and NPs. The BBB, which is far from being just a simple physical barrier, 
is an intricate, heterogeneous and dynamic tissue. The normal BBB integrity controls 
cerebral homeostasis, while dysfunction of the BBB contributes to the formation and 
progression of CNS diseases.  
Differences in age, gender, genetic background, and environment can influence 
the BBB in delicate ways. Although declines in BBB function may be multifactorial, 
aging and aging-related defects largely contribute to BBB impairment. Moreover, 
diseased conditions at the late stage of life may cause additional damage in the brain. 
Telomere shortening and telomerase deficiency are closely associated with accelerated 
endothelium aging. As presented in our work, deficiency of telomerase resulted in 
significantly pronounced BBB disruption and cerebral ischemic injury following the 
onset of stroke.  
In addition to the endogenous factors, BBB integrity is affected by exogenous 
stimuli. Since the brain endothelium forms an interface between the blood and CNS, it 
may be easily targeted by a variety of environmental pollutants, including PCBs and NPs, 
which enter human body in various manners and circulate in the blood. PCBs and/or 
NPs-mediated brain endothelium dysfunction, including overproduction of inflammatory 
mediators, transmigration of monocytes, and BBB impairment are highly linked with 
increased vulnerability to stroke-related injury. In fact, our studies also demonstrate that 
exposure to PCB-bound particles exacerbate brain damage following 
ischemia/reperfusion.  
  
99 
 
2. Telomere and telomerase in age-associated vascular dysfunction and vascular 
diseases  
Telomere biology in cancer has been well studied over the decades; however, the 
role of telomere in the field of vascular biology and aging-associated vascular diseases, 
including stroke, has been partially investigated in the recent years.  
The presence of telomerase activity in the brain during embryonic development 
characterizes the role of telomerase in neuronal differentiation and survival [224]. Both 
telomerase and TERT levels are generally decreased during embryonic and early 
postnatal development. However, telomerase activity declines dramatically as the 
neuroblasts stop proliferation and start differentiation, whereas the level of TERT 
remains high in this critical period and then decreases in association with the natural cell 
death [83]. This unparalleled change between telomerase activity and TERT levels 
suggests that TERT may function to promote cell survival through a mechanism other 
than maintaining telomere length [225]. In addition, recent studies have demonstrated 
that TERT exerts many other functions, including metabolism, secretion of growth 
factors, energy balance, mitochondria function, and apoptosis [328]. Importantly, the 
induction of telomerase in response to brain injuries have been shown in each of the 
major cell types in the brain, including neurons, astrocytes, microglia and neural stem 
cells [86, 210, 329], suggesting the intriguing possibility that TERT has protective effects 
of preventing cell death in response to hypoxia or brain injury.  
Telomerase-deficient mice are crucial models for evaluating the disease states 
associated with both normal aging and premature aging syndromes. The first generation 
of telomerase-deficient mice have been found to exhibit a normal phenotype, which is 
most probably due to the regular length of the telomere [330, 331]. However, telomere 
attrition with the successive generations results in infertility at the sixth generation 
because of the impairment of the reproductive system. Additionally, late-generation mice 
show aging-related phenotypes. For example, these animals have been reported to exhibit 
a compromised capacity in response to stress such as wound healing and hematopoietic 
ablation [332]. It has also been shown in the late generations of telomerase-deficient mice 
that the ability of neovascularization is reduced as compared to control animals [333]. In 
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the current study, we used TERT-/- mice of the second, third, and fourth generations. 
There were no apparent changes in body weight, lifespan or behavior (e.g. food uptake) 
between TERT-/- mice and wild-type animals under normal physiological conditions. 
However, upon the onset of brain ischemia, TERT-/- mice appeared to be more 
susceptible to the stress as exhibited by severe neurological deficits at 24 h, impaired 
recovery, and higher mortality as compared to wild-type mice. In contrast, TERT 
transgenic mice showed significant resistance to ischemic brain injury [86]. Additionally, 
TERT transgenic mice exhibited a reduced myocardial infarct area following coronary 
artery ligation, and exogenous expression of TERT promoted cardiac myocyte survival 
[212]. These findings indicate that TERT −/− mice are more susceptible to the 
development of stroke and TERT expression can markedly influence the survival of both 
neurons and non-neuronal cells. 
While telomeres shorten during cell divisions in cultured human endothelial cells 
and vascular smooth muscle cells (VSMCs), introduction of TERT can extend the 
lifespan of these cells, suggesting an important role of telomere shortening in the 
senescence of vascular cells and aging-related vascular disease [334]. It has been reported 
that in the endothelium of the abdominal aorta and iliac arteries, the length of telomeres 
and the age show a significant inverse correlation [335, 336]. Additionally, telomere 
length in white blood cells from patients with severe coronary artery disease is 
significantly shorter than that of controls. This may reflect not only increased leukocyte 
turnover resulting from chronic inflammation associated with atherosclerosis, but also 
accelerated cell turnover in other tissues including vascular cells [337]. Moreover, it has 
been shown that dysfunction of telomerase markedly increases the expression of ICAM-1 
and reduces the activity of eNOS [236]. In agreement with these findings, our results in 
the current study illustrate that TERT deficiency potentiate the pMCAO-induced increase 
of ICAM-1, TNF-α and IL-1β expression in the mouse brain. It was also demonstrated 
that TNF-α-mediated increase in monocyte adhesion in senescent human endothelial 
cells was attenuated in TERT transfected cells [236], further indicating a relation between 
telomerase activity and endothelial dysfunction.   
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Another novel observation in the present study indicates that TERT deficiency 
potentiates the oxidative stress in the mouse brain capillaries following the induction of 
pMCAO. Oxidative stress has been implicated in human aging as well as cellular 
senescence. In addition, increased oxidative stress is known to stimulate redox-regulated 
signaling pathways that deregulate TJ protein expression and affect the BBB integrity 
[237]. The process of endothelial cell aging, accompanied by the diminishing of TERT 
activity and proceeding to the replicative senescence, is associated with the increase of 
ROS generation. It has been suggested that increased oxidative stress results in nuclear 
export of TERT into the cytosol in endothelial cells depending on the Src family kinase 
activation, whereas treatment with antioxidants and statins can block the reduction of 
nuclear TERT activity [246]. Furthermore, repression of oxidative stress maintains the 
telomere length and elongates cell lifespan, which is partially through the activation of 
telomerase [242]. It has also been proven that NO can activate telomerase and prevent the 
endothelial cells from senescence. One of the possible explanations is that decreased 
oxidative stress, which happens when NO reacts with cellular radicals, triggers 
telomerase activation.  
Aging is one of the major risk factors for stroke and other vascular diseases. 
Taken together, it is suggested that telomere biology is important for the function of 
endothelial cells, and shortening of telomere or dysfunction of telomerase may contribute 
to the pathophysiology of vascular aging. However, the mechanisms by which telomerase 
dysfunction causes vascular dysfunction and aging-related vascular diseases have not 
been fully understood. Future challenges will be to develop and improve approaches to 
test the cellular senescence and telomere/telomerase dysfunction in vascular system aging 
in vivo. It is hoped that telomere/telomerase-based prevention will be utilized to as a 
promising target to combat aging-related vascular diseases, including stroke.  
 
3. Potentiated cerebrovascular toxicity of particle-bound PCBs 
Environmental pollution, in particular PMs and POPs, has been recognized as a 
risk factor for vascular disease and stroke. Specifically, elevated environmental levels of 
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PCBs are associated with increased levels in serum in the exposed population and higher 
prevalence to disease development, such as diabetes and hypertension [132, 256], which 
are associated with stroke. Although only limited data on the association between 
ambient air pollution and cerebrovascular disease has been reported, exposure to different 
components of air pollution, such as PMs, ozone, carbon monoxide, and nitrogen dioxide, 
is highly linked with an increased incidence of cerebrovascular ischemia [148, 154, 170].  
Results from animal experiments indicated that ultrafine PMs can translocate into 
the systemic circulation and the brain through inhalation or nasal instillation [52, 267]. 
Thus, particulate components from the ambient air pollution may act as effective carriers 
for various environmental pollutants entering the brain. PCBs are semivolatile organic 
compounds. Due to their volatility and persistence, they are subjected to long-range 
atmospheric transport and capable of binding onto different sizes of PMs in the 
environment and taken up by humans through ingestion and/or inhalation. However, 
research concerning the adverse health effect of particle-bound PCBs is currently limited. 
Our studies provide evidence indicating that PCB153-NPs may have higher 
cerebrovascular toxicity as compared to the same dosage of PCB153 exposure, which is 
proved by the significantly disrupted BBB integrity, markedly increased inflammatory 
responses, and potentiated brain injury following ischemia/reperfusion. The toxicological 
properties of nanoparticles depend on various parameters, such as size, dose, dimension, 
surface chemistry, aggregation, etc. It is not a simple additive process to estimate the risk 
of two or more pollutants. The surface of the nanoparticles plays an important role in 
toxicity since it makes direct contact with cells and tissues. Surface coating can make 
noxious nanoparticles harmless or render relatively safe nanoparticles toxic. For example, 
the presence of oxygen radicals, ozone and transition metals on the surface of 
nanoparticles creates ROS and induces inflammation [338-340]. It has been reported that 
exposure to diesel exhaust particles interacting with ozone induces elevated inflammatory 
responses in the animal lung as compared to diesel particles alone [338]. Another in vivo 
experiment showed a more prominent formation of blood clots in animals exposed to 
surface aminated polystyrene nanoparticles [341].  In contrast, the spherical gold 
nanoparticles with different surface coating exhibit non-toxic effects to human cells [342, 
343]. Additionally, nickel ferrite nanoparticles have been demonstrated to show different 
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cytotoxicity with and without surface coating of oleic acid [344]. Thus, the advanced 
vascular toxicity of PCB153-NPs may result from the synergic effects of both compounds. 
Secondly, the properties of nanoparticles as effective carriers across the BBB are well 
described [285]. Hence, binding to silica nanoparticles may facilitate PCBs crossing the 
BBB and effectively reaching the brain parenchyma. In addition, our long-term study 
shows a higher PCB153 body burden in animals chronically exposed to PCB153-NPs 
than in PCB153 alone. One of the possibilities is that PCB153-NPs have a lower 
excretion rate due to the longer retention of nanoparticles [286]. Another explanation is 
the effects of PCB153 and/or nanoparticles on intestinal epithelium, which may 
contribute to increased PCB153 absorption into the blood stream. In fact, ingestion of 
PCBs is the primary exposure route in humans. Our laboratory has already demonstrated 
that oral exposure to PCBs can disrupt TJ proteins in the small intestine and increase 
intestinal permeability [278]. 
The main toxic effects induced by coplanar PCBs are mediated via binding to 
AhR and expression of downstream genes [345]. However, the signal transduction 
mechanisms induced by ortho-PCBs are complex and include more diverse numbers of 
receptors and signaling pathways. It has been reported that ortho-PCB congeners can act 
as ligands for the constitutive andorstane receptor (CAR), the pregnane-X receptor (PXR) 
[307], and ryanodine receptors (RyRs) [308]. According to our present findings, TLR4 is 
yet another cellular receptor that is involved in ortho-PCB-mediated vascular toxicity. 
Recently, TLR4 has been increasingly recognized as a target receptor in response to the 
stimuli of various environmental pollutants. Results from a quantitative trait locus 
analysis indicate that, in very few practicable candidate genes on chromosome 4, TLR4 is 
involved in lung hyperpermeability in mice in response to ozone exposure [204]. This 
finding raises the probability that a molecule considered as a key component in innate 
immunity by sensing and regulating responses to endotoxin or LPS can also mediate the 
responses to environmental pollutants. The involvement of TLR4 in response to ozone 
exposure has been proven in studies using TLR4-deficient mice, whose hyper-reactivity 
following sub-chronic ozone exposure was markedly decreased as compared to the wild-
type control animals [346]. TLR4 signaling has not only been suggested to have a role in 
sensing the environmental pollutants, it has also been indicated to modulate the outcomes 
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of ischemic injury [180, 202]. In agreement with these findings, our results show that 
deficiency of TLR4 or inhibition of TLR4 signaling pathway significantly abrogated 
PCB153-NP-induced enhancement of ischemic brain injury, increase of inflammatory 
response, and disruption of TJ protein expression in vivo and in vitro. Our results indicate 
that TLR4 may be a potential target for investigating neurotoxicity associated with 
environmental pollutants, such as PCBs and/or NPs, and the progression of 
cerebrovascular disease. 
Although the production has been halted for approximately 50 years, PCBs are 
still ubiquitous in the environment. Recent research mainly focuses on the toxic effects 
and mechanisms of individual PCB congeners in different biological systems. However, 
since the transport modes of PCBs in the environment are multifarious, studying the 
effects of PCBs assembled onto environmental particles may provide new perspectives 
for assessing the toxicological profiles of PCB exposure. In addition to PCB153 that is 
investigated in the current work, other PCB congeners, such as dioxin-like PCBs, have 
been detected on the environmental particles, thus investigation of the health effects of 
different PCB congeners bound to NPs is also necessary. Furthermore, other than TLR4, 
various molecules have been suggested as candidates to sense and respond to ambient air 
pollutants. For example, members of the glutathione S-transferase superfamily of phase II 
xenobiotic metabolizing enzymes, including GSTP1 and GSTM1, are ideal candidate 
genes to examine the variation in humans in responsiveness to diesel exhaust particles 
(DEPs) [347]. In the future, identification of susceptible targets for various environmental 
pollutants may be emergent for health assessment and therapeutic purposes. 
 
4. Future directions—targeting the BBB  
The work presented here offers intriguing insights of modulating BBB function 
by different factors. Due to the involvement of BBB disruption as an early event in 
neurological conditions, targeting the BBB may provide insight for the prevention and 
treatment of CNS disease. In this dissertation, we mainly focus on the functional 
alterations of brain endothelium in response to the stress of environmental pollutants (e.g. 
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PCBs and NPs) and a diseased condition—cerebral ischemia. The brain endothelium 
contributes to the physical and chemical barrier properties. In fact, the BBB is dynamic, 
with a big range of permeability, which is adjusted by intracellular and intercellular 
events among not only endothelial cells, but also astrocytes, pericytes, and neurons. 
Because of the complex barrier properties and the anatomical relations of the cells 
engaged in the BBB, it is not surprising to find that the modulation of cerebral 
vasculature involves the synergistic inductive functions of more than one cell type. For 
example, it has been reported in an in vitro study that astrocytes are needed for the proper 
association of endothelial cells and pericytes in tube-like structures [348]. Under 
conditions such as physiological levels of neuronal activity or pathological stimuli [349, 
350], cross talk between neurons and glial cells, especially astrocytes [351], can influence 
cerebral blood flow. In addition to the NVU, a recent study indicates that interactions 
between leucocytes and brain endothelium play an important role in the initiation of 
seizure activity.[352]. This key observation not only signifies the importance of the BBB, 
but also highlights the need of considering blood cells and inflammatory signals as key 
players in initiating CNS pathology. Since blood cells and inflammatory signals are 
important mediators of CNS pathophysiology, it has been proposed that they should be 
considered as part of the ‘extended NVU’ [353]. Our results indicate that inflammatory 
responses may be one of the major contributors of PCB-mediated brain endothelium 
dysfunction. We demonstrate that both acute and chronic exposure to PCB153-NPs 
significantly upregulated the interaction of monocytes and leukocytes with the brain 
endothelium, a key event that contributes to the CNS pathology. Thus, other than brain 
endothelial cells, the synergistic effects within NVU, as well as the contribution of blood 
cells, should be considered as part of the future investigations of BBB study.  
One of the challenges in BBB research is to find better ways of imaging and 
monitoring functions of the living brain. In animal stroke models, opening of the BBB 
can be detected as early as minutes following occlusion of the middle cerebral artery 
[354]. Therefore, BBB disruption may stand as the early and decisive step in the acute 
cerebral ischemic stroke [355, 356]. So far, extravasation of certain dyes, such as Evan’s 
blue, is commonly used in animal studies as an index of BBB permeability that is also 
correlated with the brain infarct size. In future studies, the application of non-invasive 
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methods such as dynamic magnetic resonance, which images cerebral perfusion, and 
functional magnetic resonance imaging (fMRI), which detects signal intensity via 
changes in local blood flow and oxygenation, should be considered in the animal models 
to study the CNS etiology. With nanoparticle-based brain mapping technology, these 
methods can be further advanced to help us understand the neuro-glio-vascular coupling 
and BBB pathophysiology [357]. Moreover, changes in brain endothelial transporters 
also indicate the alteration of the BBB permeability. Recently, the in vivo assessment of 
specific BBB transport systems has been achieved by using positron emission 
tomography (PET). Studies using a radiolabeled P-glycoprotein (P-gp) ligand have 
evaluated the endothelial P-gp function and its role in the uptake and binding of drugs in 
the intact CNS [358]. At the microscopic level, the bioimaging technologies allow the in 
vivo observation of tracking of exogenous cells, including tumor cells, immune cells and 
progenitor cells. These technologies have greatly enhanced our knowledge of the 
behavior of different circulating cells across the BBB in different models of CNS disease, 
such as ischemic brain injury, autoimmune demyelination, and brain metastasis [359]. By 
using the fluorescence microscopy in the present study, we successfully visualized the 
leukocyte-endothelium-interaction in the living mouse brain, which further validated the 
inflammatory responses and vascular toxicity provoked by exposing to PCB153-NPs. In 
the future, surface modified nano-materials such as fluorescence-conjugated 
nanoparticles, could be applied in vitro and in vivo to determine the cellular and tissue 
uptake of PCB-bound nanoparticles. Additionally, for the purpose of early diagnosis or 
monitoring of disease, molecular changes in the NVU could be developed as imageable 
biomarkers using targeted molecular imaging agents [360]. However, since there is no 
single method able to capture different orders of magnitude in temporal and spatial 
resolutions while showing cellular and vascular events, it is necessary to develop better 
ways to combine and integrate data obtained from multi-modal imaging techniques.  
BBB disorders are involved in early phase of numerous CNS pathologies. Thus, 
targeting the BBB for the early treatment may help to alleviate the severity of neuro-
pathological symptoms and facilitate recovery. Since the complexity of BBB regulation is 
not fully understood, further investigations, such as detailed mechanisms involved in the 
communication among NVU in response to stress, as well as improved techniques for 
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bioimaging, could advance our knowledge of the BBB and help in the design of therapies 
for CNS diseases.  
5. Conclusions 
In conclusion, findings in this dissertation demonstrated that BBB properties can 
be affected by both endogenous and exogenous factors. Deficiency of telomerase activity, 
a key event associated with accelerated aging, aggregates cerebral ischemic stroke-
induced brain damage through disruption of BBB integrity and potentiation of 
neuroinflammaory responses. In addition, the cerebrovascular toxic effects of PCBs, one 
of the most persistent organic pollutants, can be enhanced by binding to nanoparticles, 
and the vascular toxicity of particle-bound PCBs is mediated through TLR4 signaling. 
Furthermore, our results indicate that impairment of BBB functions facilitates stroke 
outcomes. Findings resulting from the present dissertation may be applicable not only to 
stroke, but also to other neuropathological disorders where telomere biology, 
environmental pollutants, and/or BBB integrity play crucial roles. 
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Appendix Methods 
1. Surgical Procedures 
1.1. Procedure for middle cerebral artery occlusion (MCAO) 
• Autoclave all the surgical instruments and materials prior to surgery. 
• Mice were anesthetized with 1.5%~2% isoflurane in oxygen. After fixing the 
animal to the surgical platform using an adhesive tape, a midline neck incision was made 
under the operating microscope, and the soft tissues over the trachea were removed.  
• The left common carotid artery (CCA) was carefully isolated from the vagus 
nerve and ligated using a 6-0 silk thread. 
• Then, a permanent knot was placed at the distal part of the external carotid artery 
(ECA) to prevent the backflow of blood, and a vessel clip was temporarily placed on the 
internal carotid artery (ICA) close to the CCA junction.  
• The tied section of CCA was incised using the microscissors to insert the silicon 
coated filament. Once the tip of the filament reached the CCA junction, the vessel clip 
placed on the ICA was removed to allow filament insertion. 
• The filament was advanced carefully up to 10± 1 mm into the MCA from the 
CCA junction. 
• Once filament insertion into the MCA was confirmed, the mouse body 
temperature was maintained at 37 °C using a heating blanket during occlusion. 
• After a 40 min occlusion period, the filament was then withdrawn carefully to 
restore the blood flow. 
• After the removal of the filament, the knot was tightened at the CCA. Then, the 
midline neck incision was sewed using surgical suture.  
• For sham surgery, all the arteries were exposed for the surgical period but no 
filament is inserted into the MCA.  
• At the end point of the study (24h following reperfusion), the animals were 
sacrificed and histological analysis was carried out by using 2% 2,3,5-
triphenyltetrazolium chloride (TTC) staining to confirm the brain infarct volume.  
 
1.2. Procedure for vessel tubule insertion 
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• All the surgical instruments and materials were autoclaved prior to surgery. 
• Mice were anesthetized with 1.5%~2% isoflurane in oxygen. Then, a midline 
neck incision was made, followed by isolation of the left CCA, ECA, and ICA under the 
operating microscope. 
• The ECA was then ligated with 6-0 silk thread distal from the ICA.  
• Two vessel clips were placed on CCA and ICA respectively to restrict the blood 
flow. 
• A small incision was then made on the tied section of ECA, and then the tip of the 
tubing was inserted through the incision and advanced toward the CCA until it reached 
the bifurcation point.  
• The tubing was secured with an additional knot around the ECA. Then, the vessel 
clips on the CCA and the ICA were removed before performing the injection.  
• Treatment reagents were slowly instilled into the animal body through the 
inserted vessel tubule. After the injection, the tip of the tubule is gently removed from the 
ECA and a knot is tightened at the incision part of the ECA. 
• Then, the midline neck incision is sewed using surgical suture. 
 
2. Mouse cerebral micovessel isolation and immunofluorescence staining 
• Isolation buffer A 
NaCl -- 103 mmol/L  
KCl -- 4.7 mmol/L  
CaCl2 -- 2.5 mmol/L  
KH2PO4 -- 1.2 mmol/L  
MgSO4 -- 1.2 mmol/L  
HEPES -- 15 mmol/L 
Adjust pH to 7.4 
 
• Isolation buffer B 
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NaCl -- 103 mmol/L  
KCl -- 4.7 mmol/L  
CaCl2 -- 2.5 mmol/L  
KH2PO4 -- 1.2 mmol/L  
MgSO4 -- 1.2 mmol/L  
HEPES -- 15 mmol/L 
NaHCO3 -- 25 mmol/L  
Glucose 10 mmol/L  
Sodium pyruvate -- 1 mmol/L  
Dextran (MW 64 K) -- 10 g/L  
Adjust pH to 7.4 
 
• Following decapitation, the mouse brain was removed from the skull and 
immediately immersed in ice-cold isolation buffer A with protease inhibitor (Roche 
Diagnostics, Indianapolis, IN).  
• Brain stem, cerebellum, choroid plexus, and meninges were removed, and brains 
were homogenized in 5 mL of ice-cold isolation buffer B with protease inhibitor. 
• Then, 7 mL of 26% dextran was added to the homogenate and fully vortexed, and 
the samples were centrifuged at 5,800 x g at 4 °C for 20 min.  
• The supernatant was discarded, and the collected pellet was resuspended in 7 mL 
isolation buffer B and filtered through a 70 μm cell strainer (BD Biosciences, San Jose, 
CA). 
• Filtered homogenates were re-pelleted by centrifugation at 1500 x g 4 °C for 10 
min and smeared on positively charged microscope slides (Fisher Scientific, Houston, 
TX). 
• Smeared cerebral microvessels on the glass slides were allowed to dry at 100 °C 
for 10 min, and then fixed with 3% formaldehyde in phosphate-buffered saline (PBS) for 
10 min at room temperature.  
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• Slides were then washed with PBS five times, followed by permeabilization with 
0.1% Triton X-100 for 30 min. 
• The slides were then re-washed in PBS five times, and blocked in 1% bovine 
serum albumin (BSA) in PBS for 30 min at room temperature.  
• Slides were incubated in primary antibodies (e.g. anti-occludin and anti-claudin-5 
antibodies) diluted in antibody diluent with background reducing components (Dako, 
Carpinteria, CA) overnight at 4°C.  
• Slides were then rinsed in PBS five times, followed by incubation in FITC-
conjugated goat anti-mouse IgG or Texas red–conjugated goat anti-rabbit IgG (1:1,000 
dilution) for 1 hr at room temperature.  
• All slides were mounted with ProLong Gold Antifade reagent containing 4´,6-
diamidino-2-phenylindole (DAPI) to visualize the nuclei, and coverslipped with cover 
glass.  
 
3. BBB permeability assay.  
• Animals were injected i.p. with 200 µL 10% sodium fluorescein in PBS.  
• Fifteen minutes later, blood was collected via cardiac puncture. Animals were 
then transcardially perfused with 0.9% saline and brains were harvested.  
• Each brain sample was then weighed, homogenized in 1/10 dilution in PBS (w/v) 
and centrifuged at 14,000 xg for 5 min.  
• Then, 500µl supernatant was transferred into 500 µl of 15% trichloroacetic acid 
and centrifuged at 1,000 xg for 10 min.  
• After centrifugation, 125µl of 5 N NaOH was added to 500 µl of the supernatant 
and mixed well. Then, 200 ul of the mixture was loaded in 96-well plate for measurement. 
• To remove the hemoglobin contamination from the plasma, 15% TCA was added 
to plasma samples as the ratio of 1:10. The mixture was vortexed and centrifuged at 
1,000 x g for 10 min.  
• Then, add 5 N NaOH to the resulting supernatant as the ratio of 1:4. Dilute the 
fluorescein contained supernatant with PBS (1:100) if the fluorescence value is too high. 
Then 200 ul of the mixture was loaded in 96-well plate for measurement. 
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• A standard curve for quantification of sodium fluorescein in the samples was 
generated by simultaneously analysing samples of known sodium fluorescein 
concentration in PBS. 
• Fluorescence was determined using excitation at 485 nm and emission at 530 nm. 
The permeability results are presented as a ratio of brain to plasma fluorescence intensity. 
The index of BBB permeability was calculated as the ratio brain:plasma fluorescence  
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